
[http://theses.gla.ac.uk/8400/](http://theses.gla.ac.uk/8400/)

Copyright and moral rights for this work are retained by the author

A copy can be downloaded for personal non-commercial research or study, without prior permission or charge

This work cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author

The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author

When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given
MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

Clinical Research Portfolio

Claire McGoldrick
BA (Hons), MSc

Submitted in partial fulfilment of the requirements for the degree of Doctorate in Clinical Psychology

Institute of Health and Wellbeing
College of Medical, Veterinary and Life Sciences
University of Glasgow

July
2017
Acknowledgements

First and foremost, I would like to thank my research supervisor Professor Jonathan Evans. Without his expertise, patience and reassurance, this project would not have been possible.

Most importantly, I would like to thank my research participants and their partners. To engage so willingly and unreservedly in this research is both inspiring and humbling. I am extremely grateful.

A sincere thank you to my field supervisor Dr Stephanie Crawford for her advice and guidance throughout, not only this project, but my whole training experience.

Thank you to Dr Melissa Martean, Dr Eleni Morfiri, Dr Susan Conaghan, and the older adult community mental health teams in Greater Glasgow and Clyde for their support with recruitment.

A particular thank you to my friend Annette, for her endless reassurance, support, and advice throughout the last three years.

Finally, a big thank you to my family and friends. Their unwavering support, encouragement and belief got me through this whole doctoral journey.
Table of Contents

Chapter 1: SYSTEMATIC REVIEW ............................................................................................................... 1
  Abstract .................................................................................................................................................. 2
  Introduction .......................................................................................................................................... 3
  Method .................................................................................................................................................. 6
  Results ................................................................................................................................................ 7
  Discussion ............................................................................................................................................ 16
  References ........................................................................................................................................... 21

Chapter 2: MAJOR RESEARCH PROJECT .................................................................................................... 27
  Plain English Summary ......................................................................................................................... 28
  Abstract ............................................................................................................................................... 31
  Introduction .......................................................................................................................................... 32
  Method .................................................................................................................................................. 34
  Results ................................................................................................................................................ 39
  Discussion ............................................................................................................................................ 43
  References ........................................................................................................................................... 46

APPENDICES ........................................................................................................................................ 50
  Appendix 1.1 Submission Requirements for Neuropsychological Rehabilitation ............................. 50
  Appendix 1.2 Search Strategy for Systematic Review ......................................................................... 58
  Appendix 1.3 Risk of Bias in N-of-1 Trials (RoBiNT) Scale Record Form ........................................ 59
  Appendix 2.1 The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) 2016 Checklist ........................................................................................................................................... 61
  Appendix 2.2 Letter of Invitation to Study .......................................................................................... 63
  Appendix 2.3 Participant and Partner Information Sheet ..................................................................... 65
  Appendix 2.4 Participant and Partner Consent Form .......................................................................... 77
  Appendix 2.5 Weekly Monitoring Form .............................................................................................. 80
  Appendix 2.6 NHS Ethics & SSA Letters ............................................................................................. 81
  Appendix 2.7 MindMate Tutorial Presentation ................................................................................... 85
  Appendix 2.8 UTAUT Pre- & Post-Intervention Questionnaires ......................................................... 88
  Appendix 2.9 Visual Analysis of Participants ...................................................................................... 96
  Appendix 2.10 Major Research Project Proposal .............................................................................. 98
Chapter 1: SYSTEMATIC REVIEW

The Efficacy of Electronic Memory Devices for People with Dementia: A Systematic Review

Claire McGoldrick¹

¹Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow

*Correspondence Address:
Mental Health and Wellbeing
Administration Building
Gartnavel Royal Hospital
1055 Great Western Road Glasgow
Glasgow
G12 0XH
E-mail: claire.mcgoldrick@ggc.scot.nhs.uk

Declaration of Conflicts of Interest: None

Prepared in accordance with submission requirements for Neuropsychological Rehabilitation (See Appendix 1.1)

Word Count (Including references): 8,537
**Abstract**

**Background**

Memory problems are the most commonly reported difficulty in people with dementia. While electronic devices as a support for memory have been applied with success in other conditions, including brain injury, their effectiveness among the dementia population is not yet established.

**Aims**

The aim of this present review was to assess the efficacy of electronic memory devices for improving performance in tasks or activities of daily living in people with dementia and to consider the nature and methodological quality of the available evidence.

**Method**

Five databases were systematically searched. Intervention studies that examined electronic technology which has been designed to be an on-going aid to memory through reminding, alerting, storing, displaying or micro-prompting were included. Twenty-one papers were identified, which included thirty-three single case experimental design (SCED) studies. The Risk of Bias in N-of-1 Trials (RoBiNT) Scale (Tate et al., 2013) was used to rate the methodological quality of each SCED.

**Results**

Thirty-three SCEDs (mean of 15.4/30 on RoBiNT scale) were found. Baseline and intervention performance for thirty-eight participants in ten of the SCED studies was recalculated using non-overlap of all pairs (Parker and Vannest, 2009), giving a mean score of 0.99 on a 0 to 1 scale.

**Conclusions**

Results from the current review suggest that electronic devices can improve performance on activities of daily living requiring memory, however the need for further, more rigorous, investigations with this population remains.
Introduction

Demographic Shift
It is estimated that there are close to 50 million people worldwide currently living with dementia (Prince et al., 2016). With better standards of living and improved healthcare, people are living longer; hence the number with dementia is likely to double every 20 years, reaching 131.5 million by 2050 (Prince et al., 2016). While the greatest impact of dementia is progressive destruction of quality of life and the likelihood of an earlier death, there is also an economic cost to be considered. Currently, the national direct and indirect costs of caring for an individual with dementia in the UK exceeds £26 billion (Prince et al., 2014). While these costs include health and social care, the greatest cost identified (£12.4 billion) is time given by unpaid carers to people with dementia (Lewis et al., 2014).

Taking both the psychological and economic impact of dementia into account, there has been an increasing emphasis placed on early diagnosis (Salmon and Bondi, 2009). Early diagnosis, theoretically, allows access to interventions and medications that may sustain cognition, mental wellbeing and quality of life. This prolonged independence can delay the need for care home or hospital admission, which ultimately adds savings to the health economy (Knapp et al., 2015).

Dementia
Dementia is an umbrella term used to describe a group of diseases that cause cognitive impairment. Alzheimer’s disease is the most common cause of dementia, accounting for around 62% of dementia diagnoses in the UK (Lewis et al., 2014). Other common dementias include vascular dementia, frontotemporal dementia and Lewy Body dementia. While each dementia can result in a multitude of cognitive impairments, memory problems are the most commonly reported difficulty in people with dementia. Memory problems include difficulties recalling past information, as well as remembering to do something in the future (prospective memory)(Smith et al., 2000). This includes remembering to attend appointments, take medication or pay a bill.

Cognitive Rehabilitation
Cognitive rehabilitation (CR) is an individualised approach of helping people with cognitive impairments identify personally relevant goals and devise strategies for addressing them (Wilson, 2002). Unlike cognitive training, (which typically involves guided practice on a set of standardised tasks in a structured environment, aiming to improve or maintain ability in a specific cognitive domain), cognitive rehabilitation approaches tend to be implemented in real-world settings, with emphasis on improving functioning and independence in an everyday context and environment (Clare and Woods, 2004; Bahar-Fuchs et al., 2013).

Compensatory CR approaches focus on teaching people to adapt to, or bypass, their cognitive impairment using internal or external strategies. Through mastery of compensatory strategies, it is assumed that the individual will be able to manage in everyday environments, despite the presence of an underlying impairment (Dewar et al., 2016). Strategies identified include
teaching people to utilise learning techniques such as errorless learning, mnemonics and rehearsal, and external aids, including calendars, diaries and pagers.

**Memory Aids**

External memory aids are the most effective and widely used intervention for the rehabilitation of memory impairments (Sohlberg, 2005; Sohlberg et al., 2007). According to Sohlberg (2006, p.51), an external memory aid is a tool or device that “either limits the demands on the person’s impaired ability or transforms the task or environment such that it matches the client’s abilities”. Devices currently available include non-electronic (e.g. calendars, post-it notes) and electronic memory aids (e.g. pagers, smart phones). In surveys of people with memory impairments as a result of brain injury, asking someone to remind them, calendars, lists and diaries were among the most frequently used memory aids (Evans et al., 2003; Jamieson et al., 2017a).

The efficacy of non-electronic memory aids for people with dementia has been investigated in several studies (e.g. Bourgeois, 1992; Hanley and Lusty, 1984). These include the use of memory wallets and books to enhance conversation skills (e.g. Bourgeois, 1992) photographs and memory boxes to increase room finding (Nolan et al. 2001) and memory notebooks to reduce stress and distress (Johnson, 1998). While non-electronic aids have been widely available for a number of years, advances in technology have led to growing interest in the field of assistive electronic technology for supporting cognitive impairment. Electronic memory aids are potentially superior to their non-electronic equivalents as they can offer time- or event-specific reminders in various modalities, can be programmed to help organise and plan daily activities, and can be interactive.

**Electronic Memory Aids**

Electronic devices as a support for prospective memory have been applied with success in various conditions, including brain injury. For example, the NeuroPage system (Wilson et al., 1997; Wilson et al., 2001), a pager system which sends reminders for target behaviours at a pre-agreed time, has been shown to be successful at improving target behaviour performance in people with encephalitis (Emslie et al., 2007), traumatic brain injury (Wilson et al., 2005), and cerebrovascular disease (Fish et al., 2008). Other aids demonstrating similar success within the brain-injured population include voice recorders, personal data assistants (PDA), smartphones, calendars operated on a computer, and watches with alarms (see Kapur et al., 2004; Kapur and Wilson, 2009; Jamieson et al., 2017b). In a recent meta-analysis of seven group studies, a strong evidence base for the efficacy of electronic prospective memory-prompting devices for people with an acquired brain injury (ABI) was identified (d = 1.27; n = 147) (Jamieson et al., 2014).

**Electronic Memory Aids and Dementia**

In their review of assistive technology for people with dementia, Bharucha et al., (2009) acknowledged the wide range of commercially available and emerging assistive technologies for cognition (ATC), however noted a paucity of clinical trials evaluating their use within the
dementia population. They further raised concerns about the generalizability of these technologies as they were developed principally for younger people with brain injury. In a review of cognitive prosthetic technology for people with memory impairments, studies investigating their use among the dementia population accounted for only 18% (eight studies) of all studies identified (Jamieson et al., 2014). These were identified as single case experimental designs (SCED’s). Furthermore, the efficacy of the technology used could only be evaluated in three of these eight studies due to insufficient raw data available for meta-analysis in the other studies. A large effect size (Non Overlap of All Pairs (NAP)> 0.93) was noted for these three studies, providing preliminary evidence of the benefits of ATC among the dementia population.

Present Review
The aim of the current paper was to review the methodological quality and results of studies that have investigated the use of electronic prospective memory aids with people with dementia. Studies testing any prospective memory aid or device designed to support future intentions, plan retention or task organisation were considered. In their review, differentiated between prospective prompting devices (PPDs) and micro-prompting devices (MPDs). PPDs support the ability to retain future intentions in the medium and long term (e.g. Neuropage), while MPDs are designed to support plan retention and task organisation in everyday tasks with multiple steps (e.g. following a recipe). Since the review of Jamieson et al. (2014) a significant number of new studies have been published and hence a new review was considered appropriate.

A Cochrane review evaluating the efficacy of ATC for memory support in people with dementia has recently been published (Van der Roest et al., 2017). This review limited its search to randomised controlled trials (RCTs) and clustered randomised trials with blinded assessment of outcomes and identified no studies that met the inclusion criteria. Although the present review included similar outcome measures, the inclusion criteria were expanded to include single case experimental designs (SCEDs). While randomised group designs are methodologically strong, because they minimise internal validity threats, SCEDS provide a rigorous, methodologically sound alternative method of evaluation (e.g. Kratochwill and Levin, 2010). The Oxford Centre for Evidence-Bases Medicine currently ranks the n-of-1 trial as Level 1 evidence for treatment decision purposes in individual patients, alongside systematic reviews of multiple RCT’s (Tate et al., 2013).

Objectives
- To evaluate the effectiveness of electronic prospective memory aids for people with dementia on performance in tasks or activities of daily living.

- To consider the nature and methodological quality of available evidence on this topic.

- To assist in establishing the appropriateness of technological prospective memory aids as an appropriate memory intervention for people with dementia.
Method

Eligibility Criteria

Participants
Studies were limited to people with a diagnosis of dementia, regardless of clinical course or length of time since diagnosis. Studies with mixed diagnosis samples were included if individual data were reported for the participants with dementia. Memory impairments were not defined in advance and it was assumed that people receiving the technological intervention had memory impairments. Participants were aged 18 years and above.

Intervention
Any papers that examined electronic technology which has been designed to be an aid to memory through reminding, alerting, storing, displaying or micro-prompting were included. This technology could take the form of both short-term reminding (reminding the patient of each step required to complete a task such as coffee preparation) and long-term reminding (e.g. reminding the patient to attend an appointment at a certain time).

Comparators/Context
The review included studies that investigated task performance with technology compared to performance without technology or with performance with a non-technology based control treatment.

Outcome
Only studies that reported quantitative outcome measures, which reflect memory-based functioning in activities of daily living that require prospective memory, were included. Qualitative feedback in the form of interviews, focus groups, usability outcomes, amount of usage outcomes or well-being outcomes were excluded.

Study Type/Design
Studies evaluating the effectiveness of interventions were considered for review, and included RCT’s, controlled clinical trials (CCT’s), before and after designs, and SCED’s. A study was deemed to be a RCT on the basis that the trial participants were definitely or probably assigned prospectively to one or two (or more) alternative forms of intervention using random allocation (Higgins and Green, 2011). SCED studies were distinguished from descriptive case reports by the inclusion of a control phase, either through multiple baseline measures or a separate control measure that allowed the causal impact of the treatment efficacy to be inferred, as in reversal/withdrawal (ABA) designs (Tate et al., 2008).

Studies not published in the English language were excluded, as were any reviews, dissertations, conference abstracts and book chapters.
**Search Strategy**
The following electronic bibliographic databases were searched from inception up until 16th of June 2017: Medline, PsychINFO, EMBASE, CINAHL and PsycBITE. All the databases were searched via the Glasgow University online services (http://eleanor.lib.gla.ac.uk/search~S0/y). The search strategy used and modified for all databases can be found in Appendix 1.2.

Titles and abstracts were examined to identify articles featuring prospective memory devices and dementia. Reference lists of included studies were also checked to identify further relevant papers.

**Rating of Methodological Quality**
Selected papers were categorised into group studies and single case experimental designs, based on the selected criteria. Only SCED studies were identified. The tool used to rate the methodological quality of each SCED was the Risk of Bias in N-of-1 Trials (RoBiNT) Scale (Tate et al., 2013). The scale consists of 15 items in two subscales: the Internal Validity (IV) Subscale (7 items) and the External Validity and Interpretation (EVI) Subscale (8 items). Points range from 0-2 on each item, with a maximum possible score of 30. A copy of the RoBiNT record form, listing scale items and summaries of rating criteria, can be found in Appendix 1.3. This form was used in conjunction with the manual offered by Tate et al. (2013) for rating each paper.

All papers were rated by the author, and a second rater assessed 25% of the papers to establish inter-rater reliability of the checklists. Across all the checklist items in the methodological quality rating tools, there was 88% agreement between raters, suggesting adequate reliability.

**Efficacy Rating**
Non-overlap of all pairs (NAP) analysis was performed to evaluate the impact of the intervention phases on performance compared to baseline phases. NAP is a nonparametric technique that calculates a percentage of non-overlapping data by investigating the extent to which each data point in phase A (baseline) overlaps with each data point in phase B (intervention)(Parker and Vannest, 2009). NAP scores range from 0 to 1; scores closer to 0 are considered less effective, as the proportion of overlapping pairs are larger. Interventions closer to 1 are considered more effective, due to the smaller proportion of overlapping pairs. Only SCED papers that reported participant’s raw data, and included at least two data points in each phase, could be included in the NAP analysis.

**Results**

**Study Selection**
Figure 1.1 is a flowchart showing details of the search process and results.
Figure 1.1. Flow Diagram of Selection of Paper for Inclusion in the Systematic Review

Identification

- Papers identified through database search of Psychinfo, CINAHL, MEDLINE, Embase, PsycBITE (n = 2820)
- Papers identified through Reference Lists (n = 8)

Screened

- Papers remaining following transfer to RefWorks and removal of duplicates (n = 1534) → 1286 removed
- Papers identified following screening of titles (n = 107) → 1427 removed

Eligibility

- Papers identified following screening of abstract (n = 55)
- Papers remaining following reading of full texts and applying strict eligibility criteria (n = 21)

Included

- Papers included in the systematic review (n = 21)

Primary reasons for exclusion of 52:
- Reviews/Books/Conference Proceedings: 14
- No memory performance outcomes: 10
- Non technological aid: 10
- Training/Rehabilitation with no technological aid: 8
- Different population group: 5
- Case Study/report: 4
- Study Protocol: 1

Primary reasons for exclusion of 34:
- Non technological aid: 12
- No memory performance outcomes: 9
- Training/Rehabilitation with no technological aid: 5
- Case Studies: 3
- Review/Books: 2
- No quantitative data: 2
- Different population group: 1
Study Characteristics

Twenty-one papers were identified; a detailed description of the included papers is given in Table 1.1, providing details on: the type of dementia (and severity) of patient groups, setting, design, the type of technology tested, target outcome, methodological rating and technology efficacy of the studies included in this review. Overall, the studies examined 146 participants. All studies were conducted in the developed world. Four studies were conducted in Canada (Labelle and Mihailidis, 2006; Mihailidis et al., 2001; Mihailidis et al., 2004; Mihailidis et al., 2008), two in Taiwan (Chang et al., 2011; Chang et al., 2013) and the rest in Italy. Most studies took place in a day centre (43%), followed by rehabilitation/long term care unit (38%), and residential unit (14%); while one study took place in a pizza store (Chang et al., 2013).

SCED’s

All papers included in the systematic review were SCED’s. Eight of the papers identified included more than one study in their publication (e.g. Lancioni et al., 2010), and therefore each SCED study was individually assessed using the RoBiNT scale. Thirty-one (94%) investigated the efficacy of micro-prompting devices, and two (6%) investigated prospective prompting devices. A total of thirty-three SCED’s were evaluated; the mean RoBiNT scale score for all SCED studies was 15.8/30 (range = 10 – 22). The highest score recorded was for Mihailidis et al.’s (2008) study (SCED score = 22) using the COACH system to improve handwashing. This was followed by Labelle and Mihailidis’s (2006) study (SCED score = 20), which also used the COACH system. Chang et al.’s (2013) study, using the Kinept system to prepare a pizza, scored the lowest (SCED score = 10).
### Table 1.1. Details of Studies Included

<table>
<thead>
<tr>
<th>Author (Year), Country</th>
<th>Type of Dementia of Participants [severity if specified] (number)</th>
<th>Setting</th>
<th>SCED Design</th>
<th>Technology Type (name)</th>
<th>Target Behaviour</th>
<th>Method Quality Rating Score on RoBiNT scale</th>
<th>Effect size (NAP) [reason for exclusion from analysis]</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Chang et al. (2011) Taiwan</td>
<td>Dementia (1)</td>
<td>Rehabilitation Centre</td>
<td>ABAB</td>
<td>MPD – (Kinempt)</td>
<td>Food preparation</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>2. Chang et al. (2013) Taiwan</td>
<td>Dementia, paranoid schizophrenia (1)</td>
<td>Community – pizza store</td>
<td>ABC</td>
<td>MPD – (Kinempt)</td>
<td>Food preparation</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>3. Labelle and Mihailidis (2006) Canada</td>
<td>Alzheimer’s Disease (2), Mixed (3), Lewy Body Dementia (1), Not identified (2)</td>
<td>Hospital – long term care unit</td>
<td>Alternating Treatments</td>
<td>MPD - Automated prompting system (updated version of COACH; Mihailidis et al., 2000)</td>
<td>Handwashing</td>
<td>20</td>
<td>0.91 and n/a [individual results reported for one subject only]</td>
</tr>
<tr>
<td></td>
<td>Lancioni et al. (2009)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>----------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Italy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[mild–moderate] (4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rehabilitation</td>
<td>Study 1, 2, 3, 4: Non-concurrent MBD</td>
<td>MPD – battery-powered, radio-frequency photocells, light-reflecting paper, a Walkman, microprocessor-based electronic control unit</td>
<td>Study 1: Completing morning bathroom routine Study 2: Table setting Study 3: Coffee preparation</td>
<td>Study 1: 1, 1, 1, 1 Study 2: 1, 1 Study 3: 1, 1, 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Centre</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Lancioni et al. (2009a)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Italy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[mild – moderate] (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rehabilitation Centre</td>
<td>Study 1, 2, 3: Non-concurrent MBD</td>
<td>MPD – battery-powered, radio-frequency photocells, light-reflecting paper, a Walkman, microprocessor-based electronic control unit</td>
<td>Study 1: Bathroom routine Study 2: Dressing Study 3: Table-setting</td>
<td>Study 1: 1, 1, 0.99 Study 2: 1, 1, 0.91 Study 3: 0.99, 1</td>
</tr>
<tr>
<td></td>
<td>Study 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rehabilitation Centre</td>
<td>Study 1: Non-concurrent MBD Study 2: Multiple probe across activities</td>
<td>MPD – battery-powered, radio-frequency photocells, light-reflecting paper, an amplified MP3 player with USB pen drive connection, a pen containing the recording of the verbal instructions related to the activity, microprocessor-based electronic control unit</td>
<td>Study 1: Coffee preparation; Table preparation Study 2: Food preparation</td>
<td>Study 1: 15 Study 2: 15</td>
</tr>
<tr>
<td></td>
<td>Day Centre</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

7. | Lancioni et al. (2010) |   |   |   |   |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Italy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (7)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alzheimer’s disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>[moderate] (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day Centre</td>
<td>Study 1: Non-concurrent MBD Study 2: Multiple probe across activities</td>
<td>MPD – battery-powered, radio-frequency photocells, light-reflecting paper, an amplified MP3 player with USB pen drive connection, a pen containing the recording of the verbal instructions related to the activity, microprocessor-based electronic control unit</td>
<td>Study 1: Coffee preparation; Table preparation Study 2: Food preparation</td>
<td>Study 1: 15 Study 2: 15</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

8. |   |   |   |   |   |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

9. |   |   |   |   |   |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

10. |   |   |   |   |   |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

11. |   |   |   |   |   |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Authors and Year</td>
<td>Country</td>
<td>Diagnosis [Severity]</td>
<td>Setting</td>
</tr>
<tr>
<td>---</td>
<td>------------------</td>
<td>---------</td>
<td>----------------------</td>
<td>---------</td>
</tr>
<tr>
<td>8.</td>
<td>Lancioni et al. (2011)</td>
<td>Italy</td>
<td>Alzheimer’s disease [mild – moderate] (3)</td>
<td>Residential Centre</td>
</tr>
<tr>
<td>9.</td>
<td>Lancioni et al. (2012)</td>
<td>Italy</td>
<td>Alzheimer’s disease [moderate] (3)</td>
<td>Day Centre</td>
</tr>
</tbody>
</table>
| 10. | Lancioni et al. (2014) | Italy | Study 1: Alzheimer’s disease [moderate] (4)  
Study 2: Alzheimer’s disease [moderate] (4) | Day Centre | Study 1: Multiple probe across activities  
Study 2: Multiple probe across patients | MPD – Study 1: laptop fitted with Pinnacle Studio software (version 14)  
Study 2: laptop computer with amplifier, microswitch with related interface, and basic software | Study 1: Coffee/Snack preparation  
Study 2: Selecting and playing music | Study 1: 14  
Study 2: 14 | n/a [not enough data reported] |
Study 2: Alzheimer’s disease [moderate/severe] (3)  
Study 3: Alzheimer’s disease [moderate/severe] (3) | Residential Centre | Study 1 & 2: Non-concurrent MBD | MPD – laptop computer with amplifier, microswitch with related interface, and basic software | Study 1: Selecting and playing music  
Study 2: Arm-raising exercise  
Study 3: leg-foot exercise | Study 1: 13  
Study 2: 15  
Study 3: 15 | n/a [not enough data reported] |
<p>| 12. | Lancioni et al. (2016a) | Italy | Alzheimer’s disease [moderate – severe] (10) | Day Centre | Non-concurrent MBD | MPD – computer with amplifier, microswitch and basic software | Arm-raising exercise | 18 | n/a [not enough data reported] |</p>
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Diagnosis</th>
<th>Setting</th>
<th>Intervention</th>
<th>Control</th>
<th>Comparison</th>
<th>N</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>13. Lancioni et al. (2016b)</td>
<td>Italy</td>
<td>Alzheimer’s disease [low moderate – severe]</td>
<td>Day Centre (for people with AD and other dementias)</td>
<td>MPD – computer with amplifier, microswitch, and basic software</td>
<td>Non-concurrent MBD</td>
<td>Leg exercise</td>
<td>18</td>
<td>1</td>
</tr>
<tr>
<td>15. Mihailidis et al. (2000)</td>
<td>Canada</td>
<td>Alcoholic dementia [moderate]</td>
<td>Residential Unit</td>
<td>ABAB</td>
<td>MPD – Computerised cueing device (prototype of COACH)</td>
<td>Handwashing</td>
<td>11</td>
<td>n/a [not enough data reported]</td>
</tr>
<tr>
<td>16. Mihailidis et al. (2004)</td>
<td>Canada</td>
<td>Dementia [moderate – severe]</td>
<td>Long Term Care and Cognitive Support Unit</td>
<td>ABAB</td>
<td>MPD – (COACH)</td>
<td>Handwashing</td>
<td>19</td>
<td>0.97 and n/a [individual results reported for only one participant]</td>
</tr>
<tr>
<td>17. Mihailidis et al. (2008)</td>
<td>Canada</td>
<td>Dementia [moderate – severe]</td>
<td>Long Term Care Facility</td>
<td>ABAB</td>
<td>MPD – (updated version of COACH)</td>
<td>Handwashing</td>
<td>22</td>
<td>n/a [individual results not reported]</td>
</tr>
<tr>
<td>18. Oriani et al. (2003)</td>
<td>Italy</td>
<td>Alzheimer’s Disease [mild – moderate]</td>
<td>Alzheimer’s Dementia Research and Care Unit</td>
<td>PPD – portable voice recorder (EMA)</td>
<td>PP</td>
<td>Performance on various tasks including:</td>
<td>16</td>
<td>n/a [not enough data reported]</td>
</tr>
<tr>
<td></td>
<td>Study/Setting/Description</td>
<td>Group</td>
<td>Intervention Details</td>
<td>Outcome</td>
<td>Notes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>--------------------------</td>
<td>-------</td>
<td>----------------------</td>
<td>---------</td>
<td>-------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19. Perilli et al. (2012)</td>
<td>Alzheimer’s Disease [moderate] (3)</td>
<td>Day Centre</td>
<td>Non-concurrent MBD</td>
<td>MPD – Netbook computer, global system for mobile communication modem (GSM), microswitch, interface, software program (written with Borland Delphi Developer Studio, from Inprise Corporation, 2005)</td>
<td>Make a phone call</td>
<td>16</td>
<td>1, 1, 1, 1</td>
<td></td>
</tr>
<tr>
<td>20. Perilli et al. (2013b)</td>
<td>Alzheimer’s disease [mild – moderate] (5)</td>
<td>Day Centre</td>
<td>Non-concurrent MBD</td>
<td>MPD - Netbook computer, global system for mobile communication modem (GSM), microswitch, interface, software program (written with Borland Delphi Developer Studio, from Inprise Corporation, 2005)</td>
<td>Make a phone call</td>
<td>15</td>
<td>n/a [not enough data reported]</td>
<td></td>
</tr>
</tbody>
</table>

Key: MPD = micro-prompting device; PPD = prospective prompting device; COACH = Cognitive Orthosis for Assisting Activities in the home; EMA = electronic memory aid
Figures 1.2a (internal validity (IV) subscale) and 1.2b (external validity and interpretation (EVI) subscale) show base rate data (the percentage of studies meeting criteria on each item of the scale). Each item was given a score of 0, 1 or 2 based on manualised criteria defined by Tate et al. (2015). The maximum possible score on the IV and EVI subscales were 14 and 16, respectively, with higher scores representing greater validity in that domain. The mean score for all studies on the IV subscale was 6.6 (range = 2 – 10), and the mean score on the EVI subscale was 9.4 (range = 6 – 12). On the IV subscale, more than half of the studies scored low, receiving a score of 0, for items 1, 2 and 3 (design; randomisation; and sampling of behaviour). Only one study (Labelle and Mihailidis, 2006) received a point for randomisation. Most studies (92%) scored 2 on the item relating to treatment adherence. By contrast on the EVI subscale, only 1 item (generalisation) scored 0 in more than half of the studies. On this scale item, all studies received a score of 0. Over fifty per cent of the studies scored high, receiving a score of 2 on the items relating to baseline characteristics of participants; target behaviour (dependent variable); and replication.

**Figure 1.2a.** Percentage of SCED’s meeting criteria on RoBiNT Internal Validity items. Random = randomisation; Blind = blinding; Ax = assessor; pt/th = participant/therapist; IRR = inter-rater reliability; Tmt Adh = treatment adherence
NAP analysis was performed on 38 participants in 10 of the SCED studies. The studies received a mean NAP statistic of 0.99 (minimum = 0, maximum = 1). According to Parker and Vannest (2009) this represents a large effect size as it is greater than 0.93. Individual scores ranged from 0.91 to 1. When studies were divided into those evaluating prospective prompting devices and those evaluating micro-prompting devices the effect size remained large for both (0.98 and 0.99, respectively).

**Discussion**

The aims of this review were to evaluate the efficacy of electronic memory aids for people with dementia; to report on the methodological quality of the research currently available; and to assist in establishing the appropriateness of technological prospective memory aids as an appropriate memory intervention for people with dementia.

**Efficacy**

A total of twenty-one studies were identified, which totalled thirty-three single-case experimental designs. This is an increase of twenty-five SCED’s from the similar review by Jamieson et al. (2014). NAP analysis found, overall, a large effect size for the impact of both prospective prompting devices and micro-prompting devices on performance of future intentions and ability to multitask. This suggests that both types of devices are effective for people with dementia.

Due to an ageing population, with expected increases in prevalence rates, dementia is a pressing public health challenge. It is possible that the increasing number of studies evaluating interventions for people with dementia is a direct response to this growing concern. While increasing emphasis has been placed on intervening in the early stages, it is important to note that benefits were also observed in six studies that included participants with a
diagnosis of dementia considered to be in the severe stages (e.g. Lancioni et al., 2015; Mihailidis et al., 2008). As more research is completed, it is recommended that group differences are evaluated.

Despite this increase in studies, compared to the ABI literature, the number of studies identified remains considerably small. All micro-prompting devices included in this review were types of computers, including micro-processor units and laptops, that had specialised sensor devices and software for the target tasks (e.g. Kinept: Chang et al., 2013; COACH; Mihailidis et al., 2001;2004;2008). Some studies included the use of a walkman or MP3 player alongside the computer (e.g. Lancioni et al., 2009), and instructions for tasks were presented visually, or through audio. Only two studies evaluating prospective prompting devices (a voice recorder and a wearable electronic alarm device), were identified in the current review (Oriani et al., 2003: Lancioni et al., 2011). Unfortunately, none of the aids evaluated in this review are readily available to purchase for individual or clinician use, however, technological advances have led to the development of several devices (e.g. smartphones, smartwatches), used daily by the general population, that have the potential to assist prospective memory in people with dementia. They include various tools and applications that can send time-based reminders. While studies have evaluated the effectiveness of various types of everyday technologies in people with ABI (e.g. reminders delivered through Google Calendar on a smart phone (Baldwin & Powell, 2015); reminders delivered through smart watches (Jamieson et al., 2017)), only case studies were identified in this review that evaluated target memory performances utilising ubiquitous technological devices, and were therefore excluded from this review’s analyses.

For example, El Haj, Gallouj and Antoine (2017) evaluated the effectiveness of reminders delivered through the Google Calendar application on a smartphone, in a person diagnosed with mild Alzheimer’s disease, and found a decrease in forgetting of targeted events. Utilising devices already in the individual’s possession may be beneficial as the individual is already familiar with the device, and it can also eliminate potential costs and stigma experienced (Baldwin et al., 2011).

No randomised controlled trials were identified in this review. Van der Roest et al., (2017) highlighted the difficulties completing large scale studies involving assistive technology and the dementia population. These include the need for: personalisation of devices; training on how to use the devices; and intensive data collection.

First, due to the heterogeneity of impairment associated with the dementia population, personalisation of devices is often required to meet the needs of the user (e.g. Lancioni et al., 2009). Cicerone et al. (2000; 2011) offered guidelines regarding the use of memory aids for memory impaired individuals as a result of ABI or stroke; they note how the evidence suggests that memory interventions to promote the use of external compensatory strategies should be directly applied to functional activities of the individual. Similarly, Baldwin et al., (2011) found that “life style fit” was an important factor in the use of memory compensations. The
target behaviours identified in the present review appeared to have a good “life style fit”; they focused on meaningful functional tasks related to activities of daily living, including handwashing, preparing food and morning bathroom routine.

Second, there are a number of cognitive processes involved in the use of memory aids; therefore, training is often required. Indeed, this occurred in most studies of the present review. Due to the likely presence of significant executive dysfunction in people with dementia, giving the patient an aid without further instructions is likely to be insufficient. Kapur et al. (2004) described how training facilitates the development of the “metamemory” skill, whereby patients learn what situations they might need an aid; are motivated to use the aid; and they remember how to operate and use the aid effectively.

Finally, intensive data collection over a long period of time was noted in several studies of this current review. For example, in Mihailidis et al.’s (2008) study, data collection took place over 60 days, and in Perilli et al.’s (2013b) study, there were between 20-50 sessions in the intervention phase alone. These three challenges highlight the difficulties of conducting RCT’s, making SCED’s a more preferable option among researchers.

Methodology

Rizvi and Nock (2008) maintain that SCEDs provide the same level of rigour as the RCT due to their underlying scientifically robust principles. If implemented properly they will have a high level of internal validity. The results of the current review demonstrate that the internal validity of the studies identified, according to RoBiNT scale standards, was quite low (poor). Over 50% of studies obtained a zero score on three of the seven items within the subscale. However, taking each of these three scale items into account, it is important to look at the feasibility and appropriateness of each item within the context of the studies included in the present review.

Only one study received a point for randomisation in their study (Labelle and Mihailidis, 2006). However, Wolery (2013) highlighted instances where randomisation could actually produce bias. For example, in an alternating treatments design, “if the intervention is used in several consecutive sessions (which is possible with randomisation), the dimension of rapid alternation is lost” (Wolery, 2013, p.40). Wolery (2013) warned against weighting the role of randomisation until experimental analysis, that uses blind judging to evaluate the internal validity of studies with and without randomisation, is completed to resolve the issue.

50% of the studies incorporated a non-concurrent multiple baseline design. This resulted in a score of 0 on the scale item for design. However, Watson and Workman (1981) highlight the challenge of completing research in applied settings, such as day centres, hospitals and residential units. For example, appropriate participants, fulfilling the inclusion criteria for the study, may not enter the setting at the same time. Multiple baseline designs avoid the ethical and practical constraints of reversal designs (Kazdin, 1980); and non-concurrent multiple baseline designs provide a level of flexibility necessary for conducting research with this population. Indeed, due to the degenerative nature of dementia, it seems unethical to require
patients to wait until there are a sufficient number of participants to conduct a concurrent multiple baseline design. Unfortunately, the RoBiNT scale does not allow for this flexibility in its scoring. Furthermore, one of the concerns with conducting non-concurrent multiple baseline designs, is the challenge faced precluding the role of historical events on the intervention (Kazdin, 1982). However, due to the progressive and degenerative nature of memory impairment in an individual with dementia, this is unlikely to have impacted the internal validity of the studies in the present review.

With regards to the sampling of behaviour, Tate et al. (2013) recommend a minimum of five data points in every phase. While all the studies in the present review succeeded in recording this minimum requirement in the intervention phase, studies scored 0 as a result of insufficient sampling of behaviours in the baseline phase. Baseline phases in the studies included in the present review, usually involved observing the participant complete an activity of daily living unaided. It is possible that multiple baselines could create distress in the memory-impaired participant, and researchers may have chosen to reduce the number of baseline trials as a result. Furthermore, in certain studies, more than five baseline trials were completed, however data was combined/aggregated when presented graphically (e.g. Lancioni et al., 2013).

The external validity and interpretation items of the studies scored higher than the internal validity items on the scale. Indeed 50% or more of the studies received a score of 2 for replication, baseline characteristics and dependent variable (target behaviours). While none of the studies included measures for generalisation, it is unlikely that generalisation was expected in any of the studies. Most prompting devices were designed to aid specific tasks. The studies aimed to evaluate whether the compensatory strategy was successful in supporting the participant to bypass/adapt to their impairment to complete the specific task identified.

There is currently no agreed upon criteria for statistical analysis of single-case data (Kratochwill et al., 2013). Traditionally, researchers have relied upon the use of visual analysis and strong internal validity of designs to report intervention effectiveness (Olive and Smith, 2005). Visual analysis of data can determine whether a relationship between an independent variable and an outcome variable exists and also the magnitude of that relation (e.g. Gast, 2010). Guidelines for conducting visual analysis describe how various outcome-measure features must be examined within- and between-phase data; level; trend; variability; immediacy of the effect; and overlap; and consistency of data patterns across similar phases (e.g. Fisher, Kelley, and Lomas, 2003; Hersen and Barlow, 1976; Kazdin, 1982). However, for the majority of the studies in the present review only “level” and/or “overlap” were reported. Of the studies that included a statistical technique, the rationale for use was not presented.

**Limitations**

NAP analysis could only be completed in 10 (29%) of the studies included in the current review. The challenges of ensuring strong internal validity of SCEDs in applied health settings has
already been highlighted in this review. Effect size calculations, such as NAP analysis, offer an alternate means of documenting intervention effectiveness, especially when challenges to strong internal validity are present. It is important that future similar studies with this population include a method for effect size calculation when faced with challenges to strong internal validity. This is in line with the recommended guidelines for conducting and reporting SCED research (SCRIBE; Tate et al., 2016).

The RoBiNT scale used to evaluate the studies in the present review was published in 2013. Most of the current papers (seventeen) were published before or during 2013. The tool was an update to the original SCED scale (Tate et al., 2008), and followed publication of various reporting standards and guidelines for single case experimental research (Kratochwill et al., 2013; Wolery, Dunlap, and Ledford, 2011, SCRIBE: Tate et al., (2016) – in preparation at the time). It will be important to repeat the review in the future to evaluate the impact of these guidelines on subsequent SCED studies completed.

Additionally, there was a lack of inter-rater reliability in the process of screening the abstracts for inclusion, as not all abstracts were second-screened by an independent evaluator. This may mean a small number of studies, which met inclusion criteria, were missed.

Finally, the majority of the studies included in the present review were conducted within the same research group (e.g. Lancioni et al., 2009; Lancioni et al., 2013). Kratochwill et al., (2013) recommend a threshold of at least three research teams, with no overlapping authorship, at three different institutions, for systematic reviews of SCED’s. To this extent, the current review achieves that.

**Conclusion**

Despite the proliferation of electronic devices available and in use by the general population today, research exploring their potential as a memory aid for individuals presenting with memory impairments, associated with a dementia, remains limited. A large increase in studies evaluating electronic memory aids since Jamieson et al.’s (2014) study was found; these were primarily micro prompting devices on computers. The reviewed studies reported improved performance on activities of daily living, suggesting that electronic devices are an effective intervention for memory impaired individuals with dementia. This is an important finding, in terms of shaping future clinical guidelines that influence clinical practice. While the methodological quality was rated as quite low on several items of the RoBiNT scale, the reality of complying with many of these items in this type of intervention and this population group needs to be considered.

In summary, research evaluating electronic memory aids in the dementia population remains in the early stages. As an ageing population, prevalence rates of dementia are expected to increase, therefore, identifying appropriate and effective interventions to support these individuals is imperative. While this requires more rigorous and robust research, and future RCT’s are recommended, the challenges and flexibility required conducting research with this population needs to be considered in both the design and research evaluation stages.
References


Mihailidis, A., 2001. The development of an intelligent cognitive orthosis to facilitate handwashing for persons with moderate-to-severe dementia. PhD. University of Strathclyde, Bioengineering Unit.


Chapter 2: MAJOR RESEARCH PROJECT

MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

Claire McGoldrick*

1 Mental Health and Wellbeing, Institute of Health and Wellbeing, University of Glasgow

*Correspondence Address:

Mental Health and Wellbeing
Administration Building
Gartnavel Royal Hospital
1055 Great Western Road Glasgow
Glasgow
G12 0XH
E-mail: claire.mcgoldrick@ggc.scot.nhs.uk

Declaration of Conflicts of Interest: None

Prepared in accordance with submission requirements for Neuropsychological Rehabilitation (See Appendix 1.1)

Word Count (Including references): 7,548
Plain English Summary

Title
MindMate: A Single Case Experimental Design Study in People with Mild Dementia

Background
Prospective memory (PM) refers to the ability to remember to do something in the future, and is often impaired in people with dementia. PM tasks include remembering to attend an appointment, take medication, and turn off the oven after cooking. While there is no cure for dementia, there is an increasing emphasis on early diagnosis to enable access to interventions that focus on improving independence and quality of life. Electronic PM aids (e.g. pagers, personal digital assistants (PDA’s)) have been shown to be effective for assisting different populations with various memory impairments; however, little research has explored their use among the dementia population.

Mindmate (2015) is a relatively new dementia specific mobile application (app) that has been developed for smart devices, including tablets and smart phones. The application includes a reminder tool that can deliver timed-reminders to the person’s smart device.

Aims
This study explored the use of the MindMate app as a memory aid for people who have received a diagnosis of dementia, considered to be in the early stages. The aim of the study was to see if their performance on certain memory tasks improved following the introduction of the MindMate app on their smart phone or tablet. The study was also interested in whether people liked the app and would consider using it in the future.
Method

Three participants from Older People Community Mental Health Teams within Greater Glasgow and Clyde, who had received a diagnosis of mild dementia from their psychiatrist, were recruited to the study. They owned a smart phone or tablet and their partner also participated in the study.

The researcher and the participant identified certain tasks that needed to be remembered each week and these were recorded on a weekly monitoring form that was given to their partner. During the baseline period (5-7 weeks), the carer put a tick next to the task if the participant remembered, and a cross if they needed reminding or forgot about it. During the intervention (5 weeks), the participant received a reminder on their phone or tablet from MindMate about each event, and the carer continued completing the weekly monitoring form. Participants completed a pre- and post- intervention questionnaire that evaluated the participant’s views of the app and whether they would use it again in the future.

Results

Two participants successfully used the app throughout the intervention weeks and gave positive usability ratings. There was a significant increase in memory performance between baseline and intervention phase. A third participant withdrew from the intervention phase following difficulties turning off the reminders and frustrations with the alert sound.

Conclusions

Results from this study provide evidence supporting the effectiveness of MindMate as a memory aid for people with dementia. While participant’s
comments were mostly positive, some concerns were raised when the reminder did not function properly.

This research highlights the benefits of supporting people with memory difficulties as a result of their diagnosis of dementia, using an electronic device, and further research is encouraged.

*(508 words)*
Abstract

Background

Prospective memory difficulties are commonly reported in people with dementia. The evidence supporting the use of prospective memory devices among the dementia population remains limited. MindMate is a recently developed smart device application that aims to support individuals with a diagnosis of dementia, improving self-management skills and quality of life.

Aims

This study investigated the effectiveness and usability of the reminder tool on the MindMate application as a memory aid.

Method

Three participants with a diagnosis of mild Alzheimer’s disease were recruited to this multiple baseline single case experimental design study. Partners of the participants recorded their performance on everyday tasks on weekly monitoring forms during a baseline phase (for between five and seven weeks) and during the intervention phase (five weeks) whilst using MindMate.

Results

Two participants successfully used the app throughout the intervention weeks and gave positive usability ratings. Tau-U analysis showed a significant increase in memory performance between baseline and intervention phase (Tau-U = 1, 0.94, p<0.01). A third participant withdrew from the intervention phase following difficulties turning off the reminders and frustrations with the reminder alert sound.

Conclusions

The use of the MindMate app was feasible for people with dementia in the community. It was effective compared to practice as usual, with participants reporting intentions to use in the future. Limitations and implications for future research are discussed.
Introduction

Background
Prospective memory (PM) refers to the ability to remember to do something in the future (McDaniel and Einstein 2011) and is often impaired in people with dementia. PM tasks include remembering to attend an appointment, take medication, and turn off the oven after cooking. PM relies upon various cognitive functions, including executive functioning, working memory, attention and long-term memory (Einstein and McDaniel 1990); therefore, it is unsurprising that individuals with dementia experience difficulties with PM tasks. PM is highly important for maintaining functional independence (Chasteen et al. 2001). Failure to complete an intended action can negatively impact activities of daily living and have serious health consequences (Spíndola and Brucki 2011). Furthermore, carers of individuals with dementia report failures in PM as more burdensome than retrospective memory failures (i.e. the ability to recall past events or information) (Smith et al. 2000).

Taking into consideration the impact of prospective memory difficulties on people with dementia, it is important to identify appropriate interventions to address these difficulties. While there is currently no cure available for dementia, there is an increasing emphasis on early diagnosis to enable access to interventions that focus on improving independence and quality of life (BPS, 2016). Appropriate support can have a significant impact on the degree to which someone is able to manage their condition over time and live independently, delaying the need for care home or hospital admission, which adds savings to the health economy (Knapp et al. 2013). It also reduces both individual and caregiver distress (Jamieson et al. 2017a).

Memory Aids
External memory aids are a widely used and effective intervention for assisting people with memory impairment (Sohlb erg et al., 2007). As a compensatory approach, they aim to bypass the deficit area and teach the individual strategies to solve functional problems (Kapur and Wilson, 2009). Mastering these strategies will, it is assumed, help the individual manage in their everyday environment despite the presence of the impairment (Dewar et al., 2016). While paper-based aids, including calendars, to-do lists and diaries, are omnipresent in populations with and without memory impairment, they are limited by being passive reminders - they require individuals themselves to initiate using or checking them which, in itself, is a memory task (Wilson et al. 1999). Electronic memory aids offer a means of overcoming this difficulty, as they often include a cueing device that attracts the individual’s attention to the task and can include a facility for storing information (Kapur, Glisky, and Wilson, 2004).

Assistive Technology
Various electronic technology aids compensating for prospective memory difficulties have been shown to be effective in the acquired brain injury (ABI) population. For example, several studies have explored the use of NeuroPage, a portable pager that sends audio/vibration
alerts to remind the person to do something, and have reported a significant improvement in target behaviours relative to baseline (e.g. Evans, Emslie, and Wilson, 1998; Wilson et al., 2001). Similar success has been demonstrated in personal digital assistants (PDAs) (e.g. Gillette and DePompei, 2008; Wright et al., 2001); smart watches (Jamieson et al. 2017b); and smartphones (Savage and Svoboda, 2013; Svoboda and Richards, 2009). In their systematic review, Jamieson et al. (2014) found good evidence for the efficacy of prospective memory reminding systems; a meta-analysis of seven group studies, of participants with ABI, gave a large overall effect size (d = 1.27) (n = 147).

**Assistive Technology & Dementia**

While numerous studies have evaluated the use of technological memory aids among the ABI population, research into their effectiveness among the dementia population remains scarce. Indeed, most research has been confined to micro-prompting devices, which guide people through a single task with several sub-steps. These studies have demonstrated success completing tasks including; hand-washing (COACH; Mihailidis, Carmichael, and Boger, 2004); food preparation (e.g. Kinempt: Chang et., 2013); and table-setting (Giulio E. Lancioni et al. 2009).

**Smart Phones and Applications**

As previously mentioned, studies investigating the use of mobile and smartphones, in particular delivering alerts, have proven effective in people with memory problems. Various applications (apps) can be used with smartphones, such as Google Calendar and Microsoft Office Calendar. In a study of people with an ABI, McDonald et al. (2011) conducted a small randomised controlled trial using the Google Calendar application, in which participants recorded completion of prospective memory tasks. After event details are recorded, Google calendar sends timed reminders to the person’s mobile phone. In their study, McDonald et al., (2011) found Google Calendar to be significantly more effective than a paper-based diary. Similar positive outcomes were reported with an individual with ABI, who had severe verbal and visual memory difficulties and no prior use of a memory aid (Baldwin and Powell 2015). However, only one case report was identified investigating the effectiveness of an app (Google Calendar) with a participant with mild Alzheimer’s disease (El Haj et al. 2017). This study showed a reduction in forgetting of chosen target behaviours.

More recently, a dementia specific application called MindMate (2015) was developed, with the aim of supporting users in their everyday lives, improving self-management skills, and therefore maintaining the independence of users for as long as possible. This application includes a reminding tool similar to the one on Google Calendar.

**Current Study**

The present study aimed to examine the use of MindMate as a memory aid for people who have received a diagnosis of dementia, who are considered to be in the early stages, and who are specifically experiencing memory and executive functioning difficulties. A secondary aim
of the study was to help understand whether an application synced to a tablet or smartphone is a usable and acceptable off-the-shelf assistive technology.

The main hypotheses were:

- Performance on target memory tasks will improve significantly with the introduction of the MindMate reminding tool.
- The app will be a usable and acceptable form of assistive technology for people with dementia.

Reporting follows the guidelines detailed in the Single-Case Reporting Guideline in Behavioural Interventions (SCRIBE) 2016 Checklist (Tate et al. 2016) (Appendix 2.1).

Method

Participants

Participants were identified and recruited from their community mental health team to the study. Adults aged 18 or over who had received a diagnosis of mild dementia, by a psychiatrist using ICD-10 criteria, and reported memory difficulties which had been confirmed by a professional or family member, were considered for participation. Participants owned a smartphone or tablet computer with internet, and had a partner willing to support and monitor memory aid use.

Exclusion criteria were participants who:

- Had a pre-existing neurological or severe psychiatric problem (e.g. bipolar disorder, psychosis).
- Had a diagnosis of dementia considered to be in the moderate to severe stages.
- Had visual or auditory difficulties (which cannot be corrected with the use of glasses or hearing aids) that would prevent use of a smartphone.
- Had a diagnosed or suspected developmental learning disability.
- Those whose first language was not English.
- Those who were currently using online or electronic memory aids. Previous memory aid use was documented but did not exclude individuals from participation.

Four participants were initially recruited. One participant and their partner withdrew prior to commencing baseline, as the partner believed the participant was too far advanced to participate. A second participant, CE, withdrew during the first week of the intervention phase. Initially, difficulties with turning off the reminder alarm were found, due to a bug on the app, and required fixing by the app developers. Following this, CE said she found the alarm sound frustrating and with reduced motivation, decided not to continue using the app. However, both CE and her partner agreed to continue with the baseline phase for another five weeks. The cognitive profile of this participant, as well as the remaining two participants, FD and SI, are reported in Table 2.1. Participants were assessed using the following neuropsychological tests and questionnaires:

- Test of Pre-Morbid Functioning (TOPF, Wechsler, 2011);
Many of these tests had already been completed by participants FD and CE prior to participation in the study (within the previous six months), as part of their diagnostic assessment by their neuropsychological team. During the study, only tests, not completed within the previous six months, were administered by the experimenters, to give an overall impression of participants’ intellectual functioning, memory and executive functioning.

Table 2.1. Characteristics and Cognitive Profile for Participants FD, SI & CE

<table>
<thead>
<tr>
<th></th>
<th>FD</th>
<th>SI</th>
<th>CE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (gender)</strong></td>
<td>74 (male)</td>
<td>71 (male)</td>
<td>59 (female)</td>
</tr>
<tr>
<td><strong>Diagnosis (severity)</strong></td>
<td>Alzheimer’s disease (mild)</td>
<td>Alzheimer’s disease (mild)</td>
<td>Alzheimer’s disease (mild)</td>
</tr>
<tr>
<td><strong>Test</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WASI-II perceptual reasoning score</td>
<td>*</td>
<td>Average</td>
<td>Average</td>
</tr>
<tr>
<td>WASI-II verbal comprehension score</td>
<td>Low Average</td>
<td>Low Average</td>
<td>Low Average</td>
</tr>
<tr>
<td>WASI-II Full-Scale - 4</td>
<td>Low Average</td>
<td>Low Average</td>
<td>Low Average</td>
</tr>
<tr>
<td>TOPF estimated full-scale pre-morbid IQ</td>
<td>Average</td>
<td>High Average</td>
<td>Average</td>
</tr>
<tr>
<td>RBMT score (percentile rank)</td>
<td>Impaired (0.1)</td>
<td>Impaired (0.2)</td>
<td>Impaired (0.4)</td>
</tr>
<tr>
<td>Trails A score (percentile rank)</td>
<td>Average (*)</td>
<td>Low Average (20th)</td>
<td>High Average (90th)</td>
</tr>
<tr>
<td>Trails B score (percentile rank)</td>
<td>Average (*)</td>
<td>Impaired (&lt;10th)</td>
<td>Average (40th)</td>
</tr>
<tr>
<td>Verbal Fluency score (percentile rank)</td>
<td>Impaired (*)</td>
<td>Average (30th)</td>
<td>Average (40th)</td>
</tr>
<tr>
<td>PRMQ – self-rating (t-score)</td>
<td>Impaired (7)</td>
<td>Borderline Impaired (34)</td>
<td>Average (56)</td>
</tr>
<tr>
<td>PRMQ – carer (t-score)</td>
<td>Impaired (27)</td>
<td>Average (49)</td>
<td>Borderline Impaired (33)</td>
</tr>
</tbody>
</table>

Key: WASI-II = Wechsler Abbreviated Scale of Intelligence – Second Edition; TOPF = Test of Pre-morbid Functioning; RBMT = Rivermead Behavioural Memory Test; PRMQ = Prospective and Retrospective Memory Questionnaire; * = not reported in the neuropsychological assessment report for participant

Recruitment Procedures

Potential participants were given written information (Appendix 2.2) about the study via a member of the Older People Community Mental Health Team (OPCMHT) or post diagnostic service they were known to, within NHS Greater Glasgow and Clyde. Following expression of interest, they were provided with further written information (Appendix 2.3) and they completed an opt-in slip, consenting to be contacted, which was sent to the researcher. The researcher contacted the potential participants who were provided with the opportunity to discuss the study further and ask questions. Once participants and their partners agreed to participate, they were asked to sign a consent form (Appendix 2.4).
**Materials**

MindMate is a free to download and use dementia application for tablets, iPhone and android devices (http://www.mindmate-app.com/). It includes a “Reminder” tool which allows events to be entered for a specific time and date, then sends reminder alerts about the event, thus acting as a memory prompt. Each participant used their own phone/tablet as it was assumed they would already be familiar with its use.

A weekly monitoring form (Appendix 2.5) listing individual prospective memory targets and the times they need to be completed by was provided to the partner. Baldwin and Powell (2014) highlighted the importance of picking memory targets that were personally meaningful for the individual, therefore memory targets were constructed in conjunction with the participant and the partner. This approach was also used in the NeuroPage studies (Wilson et al. 2001). On days where no targets could be identified, the researcher set a reminder for the participant to send a text message or make a phone call to the researcher. The weekly monitoring form was used daily by an identified partner to record whether or not activities were remembered and completed at an appropriate time, during both the baseline and intervention phases. They were asked to tick targets achieved without prompting from other people, and cross targets that were either forgotten, remembered but not completed, completed at the wrong time, or only completed following prompting from partner.

**Design**

A randomised single case experimental design (SCED) multiple baseline across participants study was used, staggering the onset of the intervention. The Medical Research Council (MRC) Framework for Complex Interventions (MRC, 2008) supports the use of SCED studies in the feasibility and piloting and evaluation stages of complex interventions (Craig et al., 2008). While best practice is to develop interventions systematically (i.e. development; feasibility/piloting; evaluation; implementation) the present study focused on both the usability and the effectiveness of the intervention. This was in part, due to the widespread availability of the app (the app was free to download from app stores) and also due to the small number of participants recruited to the project.

Withdrawing intervention might raise ethical issues, therefore a multiple baseline, as opposed to a withdrawal (e.g. ABA) design was deemed more appropriate. The three participants were randomly allocated to a five, six or seven-week baseline using the Research Randomizer programme provided by the Social Psychology Network (http://www.randomizer.org). MindMate was then introduced for participants for a five-week period.

The study was developed with reference to the methodological quality criteria for single case experimental design studies (Risk of Bias in N of 1 trials – RoBiN-T, Tate et al., 2013) (Appendix 1.4).
Ethics

Ethical approval was obtained from the West of Scotland Research Ethics Committee 3 (16/WS/0219) and Specific Site Approval (16/WS/0219) (see Appendix 2.6) granted from NHS Greater Glasgow and Clyde. Informed consent was obtained from all three participants and their partners.

Setting, Sessions, and Data Recording

An initial interview with the participant and their partner identified target behaviours as well as previous memory aid use (see Table 2.2 for example target events). Baseline data was gathered over 5-7 weeks, during which time, all target events that were forgotten and instances of reminding were recorded. Prior to the start of the intervention phase, each participant completed training in using the MindMate app. This involved a demonstration of the reminder tool on their smart phone or tablet; participants were sent reminders asking them to undertake a number of tasks (e.g. call the researcher) to ensure they could read the message and respond appropriately (i.e. press the correct button). Then, the intervention phase lasted five weeks.

Table 2.2 Sample Target Events for Participants

<table>
<thead>
<tr>
<th>Initials</th>
<th>Sample Target Events</th>
</tr>
</thead>
<tbody>
<tr>
<td>FD</td>
<td>- Call a family member</td>
</tr>
<tr>
<td></td>
<td>- Attend an appointment</td>
</tr>
<tr>
<td></td>
<td>- Gardening</td>
</tr>
<tr>
<td></td>
<td>- Go to the shop</td>
</tr>
<tr>
<td>SI</td>
<td>- Go to choir</td>
</tr>
<tr>
<td></td>
<td>- Attend a meeting</td>
</tr>
<tr>
<td></td>
<td>- Bring/collect granddaughter from ballet</td>
</tr>
<tr>
<td></td>
<td>- Make soup</td>
</tr>
</tbody>
</table>

At the beginning of each week of the intervention, the researcher met with the partner and participant in their local OPCMHT office or in their home. They were asked about upcoming events for the week which were entered into MindMate by the researcher (see Table 2.2 for sample target events). The participant was asked how far in advance they would like to receive the reminder. Reminders were delivered at various times across the day, and so participants were encouraged to have their tablet or smartphone on them at all times. Similar to baseline, the partner recorded all target events that were forgotten as well as instances of reminding. The partner also recorded instances where the MindMate reminder failed to come through on the correct day or time, or any other technical difficulties noted with the application.

Towards the end of the intervention phase, participants received 2-3 further training sessions on how to use MindMate. This included the provision of a step-by-step guide, alongside illustrated instructions on how to locate, enter, and navigate the app and its Reminder tool (Appendix 2.7). This included inputting and deleting reminder events. The acquisition of this
skill did not form part of the aims of this study; however qualitative information was gathered upon completion of the training.

Following completion of the intervention block, qualitative information was gathered to evaluate the usefulness of MindMate, to identify its strengths and limitations and to ascertain whether the participant would use the aid in the future. Participants were asked to complete a pre- and post-study questionnaire (Appendix 2.8) on eight domains, adapted from the Unified Theory of Acceptance and Use of Technology (UTAUT) questionnaire (Venkatesh et al., 2003). These were administered at the initial clinical interview and the follow up clinical interview. The UTAUT includes groups of items concerning: performance expectancy (expectancy that the technology will be useful for its purpose); effort expectancy (perception of effort needed to use it); attitude towards the technology; social influence (the influence of others on the use of the technology); facilitating conditions (the extent to which their environment facilitates use of the technology); self-efficacy (estimations of their own ability to use the technology); anxiety (levels of anxiety felt when using the technology) and behavioural intention (an indication of whether the participant is intending to use the technology in the next 6 months). Scores for each item (on a scale of 1 to 5) within each domain can be pooled to give overall scores for each domain at each time point.

Data Analysis

Frequencies were calculated for percentage of target behaviours remembered each week. It was anticipated that the frequency of events to be remembered would differ on a weekly basis, so percentage of events remembered were calculated each week. As well as visual inspection, statistical analysis was also undertaken.

Visual inspection includes the calculation and transformation of each participant’s performance to a graph for the purpose of visually analysing (a) trend (progress over time), (b) level (magnitude of the data), and (c) stability (variability or “bounce” of the data) (Gast, 2005). The procedure for visual inspection follows steps as outlined by Lane and Gast (2014) using the graphic display and divided into (a) within-condition and (b) between-conditions analysis of data.

Tau-U analyses were conducted to investigate whether significant improvements in performance of memory tasks were found between the different phases. Tau-U is a method for measuring data non-overlap between two phases (A and B) (Tau-U; Parker et al., 2011b). Non-overlap methods do not rely on means, medians, or modes but rather consider individual values of all data points in pairwise comparisons across phases (Parker et al., 2011b). Non-overlapping data as an indicator of performance difference between phases is included in standards for evaluating SCED’s (Horner et al., 2005). Tau-U is a distribution free non-parametric technique, with an index well-suited for small datasets, and is useful in aggregating data across phases to provide an overall effect size. Depending on the data, it possesses statistical power of 91-115 percent of parametric tests (Vannest, Parker and Gonen,
2011). All calculations were performed via the website: http://singlecaseresearch.org/ (Vannest, Parker, and Gonen, 2011).

The UTAUT scores were reported descriptively.

**Power**

In their meta-analysis of SCED studies of prompting technology in acquired brain injury Jamieson et al (2014) reported medium effect sizes using non-overlap of all pairs methodology. In the present study we anticipated similar levels of effect. It was therefore anticipated that the Tau-U analysis would have sufficient statistical power to detect the anticipated effect size.

**Results**

*Cognitive Profiles of Participants*

Table 1 (p. 31) summarised the cognitive profile of participants

*Quantitative Summary of Results*

Data were collected between February and June 2017. The three graphs in figure 2.1 summarise the data of the three participants, FD, SI and CE, respectively. The data points represent the percentage of completed target events during baseline and intervention phases. Participant FD completed 49% (41/83) of tasks during baseline phase, and 93% (31/33) of tasks during intervention phase, without partner prompting. Participant SI completed 69% (84/121) of tasks during baseline phase, and 95% (35/37) of tasks during the intervention phase. Participant CE completed 51% (71/137) across eleven weeks of baseline phase.

*Participant FD*

Visual inspection of each participant’s data followed steps outlined by Lane and Gast (2014). Evaluation of phase A and B for participant FD indicated data were variable during baseline and intervention. Split-middle method of trend estimation was conducted and indicated there was a decreasing contra-therapeutic trend during baseline and zero-celerating trend during intervention. Data were considered variable in the baseline phase, and stable in the intervention phase, following application of a stability envelope to trend lines (Appendix 2.9). Mean, median and relative level change measures indicated a positive (improving) change from phase A to B.

Tau-U analysis was used to determine performance change between baseline (phase A) and intervention (phase B), and revealed a significant improvement in performance of tasks between baseline and intervention phases (1, p<0.01) for participant FD. According to (Parker et al. 2011a) this indicates a large effect size.
Fig. 2.1. The three graphs summarise the data of the three participants, respectively. The data points represent the percentage of target memory tasks completed each week in each study phase (A = baseline, B = intervention). The Y axis shows percent performance and X axis shows study week.
**Participant SI**
Evaluation of each phase for participant SI indicated data were stable during baseline and intervention. Split-middle method of trend estimation was conducted and indicated there was an increasing trend in a therapeutic direction during both phases. Data were considered stable following application of a stability envelope to trend lines. Mean, median and relative level change measures indicated a positive (improving) change across conditions.

Tau-U analyses revealed a significant improvement in performance of tasks between baseline and intervention phases (0.94, p<0.01) for participant SI. According to Parker *et al.* (2011a) this indicates a large effect size.

**Participant CE**
Evaluation of the baseline phase for participant CE indicated data were variable, and remained variable following application of a stability envelope to trend lines. Split middle method of trend estimation was conducted and indicated there was a marginally increasing trend in a therapeutic direction.

**Usability and User Experience**
It was also of interest to know whether or not the participants found the app acceptable. FD completed three weeks of training prior to beginning the intervention phase, and SI completed one week of training. Problems with the app were reported for all three participants (Table 3). These included occasions where the reminder did not come through at the specified time/day and when the reminder alarm failed to stop despite the participant clicking into the app. The developers recognised a bug on the app with regards to the latter problem and updated the app to remove it.

<table>
<thead>
<tr>
<th>Participant</th>
<th>Number of App Errors Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>FD</td>
<td>3</td>
</tr>
<tr>
<td>SI</td>
<td>5</td>
</tr>
<tr>
<td>CE</td>
<td>3</td>
</tr>
</tbody>
</table>

App errors included: reminder not coming through at right time/day; recurring alarm sound; reminder not appearing under correct day;

Table 4 shows mean scores for each individual UTAUT category for participants FD and SI. Lower scores represent a more positive user experience. The results indicate that FD had a better experience using the technology than IS, but both scored quite low overall. There was an overall decrease in FD's scores between pre- and post- intervention, however the mean score for the anxiety domain increased from 1 (strongly agree) to 2 (agree). SI's scores increased on performance expectancy, effort expectancy, social influence, and self-efficacy. While SI expressed intention to continue using the app following completion of the study, he expressed uncertainty about the usefulness and helpfulness of the app as he was still learning to enter reminders independently. Further training sessions were offered, and accepted, to ease any anxiety using the app.
Table 4. UTAUT Mean Scores on Each Category for FD and SI

<table>
<thead>
<tr>
<th></th>
<th>FD Pre</th>
<th>FD Post</th>
<th>SI Pre</th>
<th>SI Post</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Expectancy</td>
<td>1.67</td>
<td>1</td>
<td>2</td>
<td>2.67</td>
</tr>
<tr>
<td>Effort Expectancy</td>
<td>1.75</td>
<td>1.75</td>
<td>2.25</td>
<td>2.5</td>
</tr>
<tr>
<td>Attitude</td>
<td>1.67</td>
<td>1.67</td>
<td>1.67</td>
<td>2.33</td>
</tr>
<tr>
<td>Social Influence</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Facilitating Conditions</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Self-efficacy</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Behavioural Intervention</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Total Score</td>
<td>28</td>
<td>25</td>
<td>36</td>
<td>42</td>
</tr>
</tbody>
</table>

Lower scores in the UTAUT indicate a better user experience. UTAUT item responses are out of 5, with responses ranging from Strongly Agree to Strongly Disagree. The total is out of 85.

Follow up questions to the questionnaire provided some qualitative information.

FD said, “Wish I had it earlier” when asked about overall impression of the app. His partner said she enjoyed the “principle of it”. She described how she usually does everything for FD and tells him everything that he needs to do whereas the app “gives him something for himself...a sense of independence”.

SI said the alarm “sound was good for catching my attention” when otherwise engaged. He found it helpful “to some extent”, although reported frustration with ongoing memory difficulties. The partner of SI also reported frustration with the errors associated with the app, reported earlier. Specifically, the times when the reminders did not come through as specified. She described how the reminder app does not capture the other, perhaps unexpected, memory difficulties that SI was experiencing, such as remembering to collect luggage from airport carousel or remembering to check he has all necessary items (e.g. keys, wallet) when leaving the house. SI’s partner also reported increased incidences of confusion in SI, since commencing the study, which she attributed to the app and when the reminders did not come through as intended.

When asked about the main difficulties associated with using the App, prior to withdrawal, the partner of CE said that CE was “either in denial of memory difficulties...or lacked insight into them”. CE reported her memory to be “fine” and described the noise from the alarm as “annoying”. CE’s partner reported that usually CE would be very motivated to participate in research studies, however she was struggling to use other parts of the iPhone and so wondered whether her difficulties operating the app made her want to withdraw from the intervention phase. He noted increased apathy in CE and wondered if this was possibly a result of her dementia diagnosis. He said he wished the study had taken place a year ago, when CE exhibited fewer difficulties with memory and completing tasks.
Discussion

Efficacy

Baseline data confirmed that all participants often forgot to carry out target behaviours or only carried them out if reminded by their retrospective partners. The results of the efficacy analysis show that introduction of the reminder app for FD and SI led to a statistically significant change in memory performance for both participants, with a large effect size reported for both. It is unlikely that improvement was due to spontaneous recovery – CE showed little change over time.

With increasing emphasis on early detection and intervention for people with dementia, this study adds to the limited, but growing, body of literature suggesting the effectiveness of electronic memory aids for people with dementia. While this was the first piece of research evaluating the effectiveness of the MindMate app as a reminder tool, similar positive results have been reported with the Google Calendar app with both the ABI and dementia population (McDonald et al, 2011; Baldwin and Powell, 2014; El Haj et al., 2017).

There is an increasing number of older people using smart phones and tablet devices; they are relatively easy to use, socially acceptable and cost-effective. In a recent survey of memory aid use among the brain injured population, Jamieson et al., (2017a) noted that other technologies, including pagers, dictaphones, and electronic organisers have become obsolete, as many of their functions can now be performed on smartphones. This has facilitated the introduction of more sophisticated, cheaper and user-friendly aids, such as the MindMate app.

Smartphones and tablet devices also offer a solution for overcoming any potential stigma that might be associated with using an aid. Baldwin et al., (2011) found that a key factor leading to avoidance of memory aids among the brain injured population was that they were a threat to the individual’s pre-injured identity. The same could be considered for those with a diagnosis of dementia. The importance of offering memory compensatory strategies that reflect an individual’s sense of self, lifestyle and values has been highlighted previously (Baldwin et al., 2011). Smartphones and tablet devices address this issue, due to their omnipresence in today’s society.

Usability

The secondary aim of this research was to evaluate the usability and acceptability of this app as an assistive technology device for people with dementia. The UTAUT scores were overall positive; both participants expressed a favourable opinion of the app, and expressed intention to use the app following completion of the study. However, frustrations were noted when the app did not function as intended, and this influenced both SI’s self-efficacy and his partner’s beliefs around the potential benefits of the app.

Apps on smart devices are continually developing and upgrading; this is in response to both, growing consumer demand, and to updates on the devices’ operating systems, which can
impact the app’s functioning. For example, problems with turning off the alarm for CE were a result of a bug developing on the app, following an upgrade of the smartphone’s mobile operating system (iOS for Apple). As a result, an update of the MindMate app was required to remove this bug. These changes are difficult to control for and present a challenge in terms of a person with dementia’s ability to adapt to these changes and upgrades. The impact of upgrades and changes to an app on the individual with dementia is an important consideration for the developers of apps that target this population as well as researchers.

For example, future studies evaluating apps should be transparent with potential participants about the possibility of technical difficulties at the point of recruitment. The current researcher was in regular contact with both participants and app developers, therefore the difficulties were addressed in a relatively short space of time. However, if this regular access is not available, contact details for accessing technical support should be made available to participants at the outset.

The results of the UTAUT questionnaire should be interpreted with caution as they only reflect the views of two participants. Indeed, the third participant withdrew from the study following reported frustration with the alarm sound and difficulties turning off the reminder. This would suggest that she found it neither acceptable nor usable. The partner of CE believed that CE’s dementia was too far advanced for her to learn to operate a new app; this suggests it may be important to consider the role of insight as inclusion criterion for future research. While CE expressed enthusiasm to participate at the outset of the present study, results of her PRMQ would suggest that she did not believe her memory difficulties were at the level of impairment. Indeed, at follow-up interview, CE described her memory as “fine” and “good”. While lack of insight is a common clinical feature of people with dementia, it is possible that this might impact participation in research to support a difficulty that they might not believe they have.

Methodological Limitations
The study followed RoBiNT recommendations for both external and internal validity in SCED studies (Tate et al., 2013). While these were mostly met, certain scale items were more difficult to achieve.

It was not expected that that the reminder strategy would have any long-term effects on memory ability following completion of the study; therefore, no generalisation measures were undertaken. A description of setting was also not provided; as the reminders were delivered across the day, the participants may have been in their home or elsewhere in the community at the time of receiving them.

Tate et al. (2013) recommend the demonstration of at least three repetitions of treatment effect. Due to time constraints, the present study could only demonstrate two repetitions, following withdrawal of participant CE. This also impacted the score for design with control, as only four phases were recorded. It was also not possible to blind the participant or therapist to the study conditions because training had to be provided on using the app prior to
commencing intervention phase. The lack of blinding of the experimenter was unlikely to cause bias, as it was the app that was delivering the reminders to the participant.

It was often difficult to identify memory targets for the week ahead for participants during the intervention phase, and therefore proxy experimental memory tasks were created (e.g. send researcher a text message at a certain time). The researcher met with each participant and their partners at the beginning of each week, during the intervention phase, and they often did not have clearly defined schedules for the week ahead. This led to the recording of fewer target events during this phase. The majority of people who receive a diagnosis of dementia are in the older adult population, and are therefore, more likely to be retired. People who are retired are less likely to have fixed events in their week as they do not have job responsibilities. It might be helpful to think about future similar research encouraging participants to routinize events that take place more intermittently (e.g. certain household chores on a specific day of the week).

The partner of SI also noted that less anticipated events (e.g. leaving luggage at airport) were most distressing for SI, and these events were difficult to capture using the MindMate app. This difficulty in predicting, measuring and controlling for unexpected or unusual events that might catch people out was also reported by Jamieson et al., (2017) in their study evaluating smartwatches.

Wolery and Harris (1982) advised on the continuation of the baseline phase condition if behaviours were changing in a therapeutic direction. This did not happen for participant SI, despite an increasing trend being observed, for a couple of reasons. First, the participant was very eager to begin using the MindMate app and, having initially informed him and his partner of the 7-week time frame for baseline data collection, the researcher was concerned about patient engagement should baseline have to continue indefinitely. Second, dementia, unlike ABI, is a degenerative condition, and with focus on early intervention, it would seem unethical to make the participant continue with baseline for an unknown period of time.

Recruitment took place across three community mental health teams over a five-month period. However, only four participants were initially identified, and two completed the study. One possible reason for this could be the lack of people being diagnosed with mild dementia within the teams. Indeed, many health professionals and post-diagnostic support workers from the teams noted the dearth of patients with a diagnosis of mild dementia on their caseload; most, if not all, were in the moderate to severe stages of their illness. Jamieson et al., (2014) suggested that memory aids may support learning of associations (e.g. taking medication and mealtimes). For this reason, they highlight the added advantage of training participants to learn to use an aid while the cognitive impairment is relatively mild; the knowledge is more likely to be retained as a person’s memory deteriorates. However, other studies have shown positive effects evaluating electronic memory aids with participants with both moderate and severe dementia (e.g. Oriani et al., 2003; Mihailidis et al., 2004; 2008). For example, (Mihailidis et al., 2004) reported increased performance at handwashing using...
their computerised device (COACH) in participants with moderate to severe dementia. It would be interesting to expand inclusion criteria for future similar research to include those with a dementia considered to be in the moderate or severe stages, and evaluate differences.

Staff also reported a low number of patients on their caseload who owned a smart phone or tablet. According to an Ofcom (2016), smartphones are the most widely-owned internet-enabled device. Although 66% of adults own a smartphone, and 54% of households own a tablet, the 65+ population are reported to be the slowest in terms of uptake of smart devices. However, the number of users is projected to increase year on year (Statista, 2017).

Conclusion
The findings from this study provide evidence supporting the effectiveness of the intervention. While user experience was mostly positive, some concerns were raised in relation to the nature of the reminder offered and the frustration experienced when the reminder did not deliver, as intended. It is possible that the lack of research looking at the efficacy of memory aids with this population is a result of the many challenges experienced in this study. Nonetheless, both participants indicated overall favourability with the app, with intention expressed to continue using it to support their memory difficulties. Therefore, the MindMate app could serve as a feasible intervention for prospective memory difficulties in people with dementia in clinical practice.

References


Appendix 1.1 Submission Requirements for *Neuropsychological Rehabilitation*

**Instructions for authors**

Thank you for choosing to submit your paper to us. These instructions will ensure we have everything required so your paper can move through peer review, production and publication smoothly. Please take the time to read and follow them as closely as possible, as doing so will ensure your paper matches the journal’s requirements. For general guidance on the publication process at Taylor & Francis please visit our Author Services website.

**AUTHOR SERVICES**

Supporting Taylor & Francis authors

This journal uses ScholarOne Manuscripts (previously Manuscript Central) to peer review manuscript submissions. Please read the guide for ScholarOne authors before making a submission. Complete guidelines for preparing and submitting your manuscript to this journal are provided below.

**Contents list**

- About the journal
- Peer review
- Preparing your paper
  - Structure
  - Word limits
  - Style guidelines
  - Formatting and templates
  - References
  - Checklist
- Using third-party material in your paper
Clinical Trials Registry
Complying with ethics of experimentation
  Consent
  Health and safety
Submitting your paper
Publication charges
Copyright options
Complying with funding agencies
Open access
My Authored Works
Article reprints

About the journal

Neuropsychological Rehabilitation is an international, peer reviewed journal, publishing high-quality, original research. Please see the journal’s Aims & Scope for information about its focus and peer-review policy.

Please note that this journal only publishes manuscripts in English.

This journal accepts the following article types: original (regular) articles, scholarly reviews, and book reviews.

Peer review

Taylor & Francis is committed to peer-review integrity and upholding the highest standards of review. Once your paper has been assessed for suitability by the editor, it will then be double blind peer-reviewed by independent, anonymous expert referees. Find out more about what to expect during peer review and read our guidance on publishing ethics.

Preparing your paper

All authors submitting to medicine, biomedicine, health sciences, allied and public health journals should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, prepared by the International Committee of Medical Journal Editors (ICMJE).
We also refer authors to the community standards explicit in the American Psychological Association's (APA) Ethical Principles of Psychologists and Code of Conduct.

Structure

Your paper should be compiled in the following order: title page; abstract; keywords; main text; acknowledgements; references; appendices (as appropriate); table(s) with caption(s) (on individual pages); figure caption(s) (as a list).

Word limits

Please include a word count for your paper.
There are no word limits for articles in this journal.

Style guidelines

Please refer to these style guidelines when preparing your paper, rather than any published articles or a sample copy.

Please use British -ize spelling style consistently throughout your manuscript.

Please use double quotation marks, except where "a quotation is 'within' a quotation". Please note that long quotations should be indented without quotation marks.

The style and format of your paper should conform to the specifications given in the Publication Manual of the American Psychological Association (6th ed.).

Formatting and templates

Papers may be submitted in any standard format, including Word and LaTeX. Figures should be saved separately from the text. To assist you in preparing your paper, we provide formatting templates.

A LaTeX template is available for this journal.

Word templates are available for this journal. Please save the template to your hard drive, ready for use.
If you are not able to use the templates via the links (or if you have any other template queries) please contact authortemplate@tandf.co.uk

References

Please use this reference style guide when preparing your paper. An EndNote output style is also available to assist you.

Checklist: what to include

1. **Author details**. Please ensure everyone meeting the International Committee of Medical Journal Editors (ICMJE) requirements for authorship is included as an author of your paper. Please include all authors’ full names, affiliations, postal addresses, telephone numbers and email addresses on the title page. Where available, please also include ORCID identifiers and social media handles (Facebook, Twitter or LinkedIn). One author will need to be identified as the corresponding author, with their email address normally displayed in the article PDF (depending on the journal) and the online article. Authors’ affiliations are the affiliations where the research was conducted. If any of the named co-authors moves affiliation during the peer-review process, the new affiliation can be given as a footnote. Please note that no changes to affiliation can be made after your paper is accepted. Read more on authorship.

2. A non-structured abstract of more than 150 and no more than 200 words. Read tips on **writing your abstract**.

3. You can opt to include a **video abstract** with your article. Find out how these can help your work reach a wider audience, and **what to think about when filming**.

4. Up to five **keywords**. Read making your article more discoverable, including information on choosing a title and search engine optimization.

5. **Funding details**. Please supply all details required by your funding and grant-awarding bodies as follows:
   - *For single agency grants*: This work was supported by the [Funding Agency] under Grant [number xxx].
   - *For multiple agency grants*: This work was supported by the [Funding Agency 1]; under Grant [number xxxx]; [Funding Agency 2] under Grant [number xxx]; and [Funding Agency 3] under Grant [number xxxx].

6. **Disclosure statement**. This is to acknowledge any financial interest or benefit that has arisen from the direct applications of your research. Further guidance on what is a conflict of interest and how to disclose it.

7. **Geolocation information**. Submitting a geolocation information section, as a separate paragraph before your acknowledgements, means we can index your paper’s study area accurately in JournalMap’s geographic literature database and make your article more discoverable to others.

8. **Supplemental online material**. Supplemental material can be a video, dataset, files, set, sound file or anything which supports (and is pertinent to) your paper. We publish supplemental material online via Figshare. Find out more about
supplemental material and how to submit it with your article.

9. Figures. Figures should be high quality (1200 dpi for line art, 600 dpi for grayscale and 300 dpi for color, at the correct size). Figures should be saved as TIFF, PostScript or EPS files. More information on how to prepare artwork.

10. Tables. Tables should present new information rather than duplicating what is in the text. Readers should be able to interpret the table without reference to the text. Please supply editable files.

11. Equations. If you are submitting your manuscript as a Word document, please ensure that equations are editable. More information about mathematical symbols and equations.

12. Units. Please use SI units (non-italicized).

Using third-party material in your paper

You must obtain the necessary permission to reuse third-party material in your article. The use of short extracts of text and some other types of material is usually permitted, on a limited basis, for the purposes of criticism and review without securing formal permission. If you wish to include any material in your paper for which you do not hold copyright, and which is not covered by this informal agreement, you will need to obtain written permission from the copyright owner prior to submission. More information on requesting permission to reproduce work(s) under copyright.

Disclosure statement

Please include a disclosure of interest statement, using the subheading “Disclosure of interest.” If you have no interests to declare, please state this (suggested wording: The authors report no conflicts of interest). For all NIH/Wellcome-funded papers, the grant number(s) must be included in the disclosure of interest statement. Read more on declaring conflicts of interest.

Clinical Trials Registry

In order to be published in a Taylor & Francis Journal, all clinical trials must have been registered in a public repository at the beginning of the research process (prior to patient enrolment). Trial registration numbers should be included in the abstract, with full details in the methods section. The registry should be publicly accessible (at no charge), open to all prospective registrants, and managed by a not-for-profit organization. For a list of registries that meet these requirements, please visit the WHO International Clinical Trials Registry Platform (ICTRP). The registration of all clinical trials facilitates the sharing of information among clinicians, researchers, and patients, enhances public confidence in research, and is in accordance with the ICMJE guidelines.
Complying with ethics of experimentation

Please ensure that all research reported in submitted papers has been conducted in an ethical and responsible manner, and is in full compliance with all relevant codes of experimentation and legislation. All papers which report *in vivo* experiments or clinical trials on humans or animals must include a written statement in the Methods section. This should explain that all work was conducted with the formal approval of the local human subject or animal care committees (institutional and national), and that clinical trials have been registered as legislation requires. Authors who do not have formal ethics review committees should include a statement that their study follows the principles of the Declaration of Helsinki.

Consent

All authors are required to follow the ICMJE requirements on privacy and informed consent from patients and study participants. Please confirm that any patient, service user, or participant (or that person's parent or legal guardian) in any research, experiment, or clinical trial described in your paper has given written consent to the inclusion of material pertaining to themselves, that they acknowledge that they cannot be identified via the paper, and that you have fully anonymized them. Where someone is deceased, please ensure you have written consent from the family or estate. Authors may use this Patient Consent Form, which should be completed, saved, and sent to the journal if requested.

Health and safety

Please confirm that all mandatory laboratory health and safety procedures have been complied with in the course of conducting any experimental work reported in your paper. Please ensure your paper contains all appropriate warnings on any hazards that may be involved in carrying out the experiments or procedures you have described, or that may be involved in instructions, materials, or formulae.

Please include all relevant safety precautions; and cite any accepted standard or code of practice. Authors working in animal science may find it useful to consult the International Association of Veterinary Editors’ Consensus Author Guidelines on Animal Ethics and Welfare and Guidelines for the Treatment of Animals in Behavioural Research and Teaching. When a product has not yet been approved by an appropriate regulatory body for the use described in your paper, please specify this, or that the product is still investigational.
Submitting your paper

This journal uses ScholarOne Manuscripts to manage the peer-review process. If you haven’t submitted a paper to this journal before, you will need to create an account in the submission centre. Please read the guidelines above and then submit your paper in the relevant author centre where you will find user guides and a helpdesk.

If you are submitting in LaTeX, please convert the files to PDF beforehand (you may also need to upload or send your LaTeX source files with the PDF).

Please note that Neuropsychological Rehabilitation uses Crossref™ to screen papers for unoriginal material. By submitting your paper to Neuropsychological Rehabilitation you are agreeing to originality checks during the peer-review and production processes.

On acceptance, we recommend that you keep a copy of your Accepted Manuscript. Find out more about sharing your work.

Publication charges

There are no submission fees or page charges for this journal.

Color figures will be reproduced in color in your online article free of charge. If it is necessary for the figures to be reproduced in color in the print version, a charge will apply.

Charges for color figures in print are £250 per figure ($395 US Dollars; $385 Australian Dollars; €315). For more than 4 color figures, figures 5 and above will be charged at £50 per figure ($80 US Dollars; $75 Australian Dollars; €63). Depending on your location, these charges may be subject to local taxes.

Copyright options

Copyright allows you to protect your original material, and stop others from using your work without your permission. Taylor & Francis offers a number of different license and reuse options, including Creative Commons licenses when publishing open access. Read more on publishing agreements.
Complying with funding agencies

We will deposit all National Institutes of Health or Wellcome Trust-funded papers into PubMedCentral on behalf of authors, meeting the requirements of their respective open access (OA) policies. If this applies to you, please tell our production team when you receive your article proofs, so we can do this for you. Check funders’ OA policy mandates here. Find out more about sharing your work.

Open access

This journal gives authors the option to publish open access via our Open Select publishing program, making it free to access online immediately on publication. Many funders mandate publishing your research open access; you can check open access funder policies and mandates here.

Taylor & Francis Open Select gives you, your institution or funder the option of paying an article publishing charge (APC) to make an article open access. Please contact openaccess@tandf.co.uk if you would like to find out more, or go to our Author Services website.

For more information on license options, embargo periods and APCs for this journal please search for the journal in our Journal list.

My Authored Works

On publication, you will be able to view, download and check your article’s metrics (downloads, citations and Altmetric data) via My Authored Works on Taylor & Francis Online. This is where you can access every article you have published with us, as well as your free eprints link, so you can quickly and easily share your work with friends and colleagues.

We are committed to promoting and increasing the visibility of your article. Here are some tips and ideas on how you can work with us to promote your research.

Article reprints

You will be sent a link to order article reprints via your account in our production system. For enquiries about reprints, please contact the Taylor & Francis Author Services team at reprints@tandf.co.uk. You can also order print copies of the journal issue in which your article appears.

Queries

Should you have any queries, please visit our Author Services website or contact us at authorqueries@tandf.co.uk.

Updated November 2016
Appendix 1.2 Search Strategy for Systematic Review

**Search terms**

Dementia or Alzheimer* or (cognitive deterioration) or (cognitive decline) or (intel* deterioration) or (mental deterioration) or (degenerative disease)

AND

memory rehabilitation OR cognitive rehabilitation OR cognitive aid* OR memory aid* OR cognitive orthos* OR cognitive prosth* OR assistive technolog * for cognition OR compensat* technolog* OR memory orthot* OR memory prosth*

AND

Technolog* OR computer OR digital OR robot OR pag* OR text* OR messag* OR telephone OR smartphone OR (smart hous*) OR camera OR television OR system OR device

AND

everyday memory OR prospective memory OR retrospective memory OR attention OR reminding OR micro-prompting OR prompting OR alerting OR organisation OR time keeping OR intention* OR goal manag*
### Risk of Bias in N-of-1 Trials (RoBiNT) Scale Record Form

**Rater Name:**

**Author & Title:**

**Internal Validity (IV) Subscale**

<table>
<thead>
<tr>
<th>Subscale</th>
<th>Points</th>
<th>Description</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Design with control</td>
<td>2 Points:</td>
<td>At minimum: ABA with 4 phases: concurrent multiple-baseline design (MBD) with 6 phases, 3 libraries; alternating-treatment design (ATD) with 4 sets of alternating sequences; changing-conditions design (CCD) with 4 sets; for medical N-of-1: 2 x AB pairs</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>ABA or 3 phase variant: concurrent MBD with 4-5 phases, 2 libraries; ATD with 3 sets of alternating sequences; CCD with 3 steps; for medical N-of-1: 2 x AB pairs</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>AB; AB+follow-up; non-concurrent MBD; ATD with &lt;3 sets of alternating sequences; CCD with &lt;3 steps; nonwithdrawable treatment in ABA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Randomisation</td>
<td>2 Points:</td>
<td>Randomisation sequence (and/or) and/or randomization (e.g. random assignment; blocks of sequences); counterbalancing</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>Restricted randomisation (e.g., participants in blocks of sequences); counterbalancing</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>No information; randomization of other aspects of the study (e.g., stimulus materials)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Sampling of behaviour</td>
<td>2 Points:</td>
<td>5 or more data points in every phase with data presented</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>At least 3 data points in every phase with data presented</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>&lt;3 data points in any phase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Blinding of people involved in the intervention</td>
<td>2 Points:</td>
<td>Both participant and practitioner blind to phase of study. If technological intervention used, consult manual</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>Participant or practitioner blind to phase. If technological intervention used, consult manual</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>Neither participant nor practitioner are blind to phase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Blinding of assessor(s)</td>
<td>2 Points:</td>
<td>Assessors blind to all phases; use of computer/machine free from human involvement; outcomes self-report and participant is blind</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>Independent assessors, but not blind to phase</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>Practitioner collects/extracts/scores/processes the data; no mention of blinding or independence of assessors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Interrater agreement</td>
<td>2 Points:</td>
<td>Machine-generated data or data sampled from &lt;20% per condition, analysed and reported per condition, with ≥20% agreement (κ&gt;0.6, etc)</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>A reasonably objective measure (as defined in the manual); ≥20% agreement (κ&gt;0.4), even if (a) data are not calculated and reported per condition and/or (b) &lt;20% of data is sampled per condition</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>Agreement &lt;70% (κ&lt;0.4, etc); subjective measure used; conscious ratings alone; inter-rater agreement only reported for a previous study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Treatment adherence</td>
<td>2 Points:</td>
<td>Machine-delivered intervention free from human implementation or adherence assessed (i) against a clear rating system, (ii) assessor independent of practitioner/participant, (iii) ≥20% of IS data sampled, (iv) resulting in ≥20% adherence</td>
<td>0 1 2</td>
</tr>
<tr>
<td>1 Point:</td>
<td>Adherence measured; ≥4 criteria above, and includes (a) assessor independent of practitioner and (b) adherence ≥70%</td>
<td>Where:</td>
<td></td>
</tr>
<tr>
<td>0 Points:</td>
<td>Adherence &lt;70%; assessor not independent of practitioner; components only loosely related to adherence</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### External Validity and Interpretation (EVI) Subscale

<table>
<thead>
<tr>
<th>Score</th>
<th>Where:</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 1 2</td>
<td></td>
</tr>
</tbody>
</table>

#### 6 Baseline characteristics
- **2 Points:** Analysis of baseline characteristics and age, sex, etiology, severity of condition
- **1 Point:** Analysis of baseline characteristics or age, sex, etiology, severity of condition
- **0 Points:** No analysis of baseline conditions or incomplete listing of the four participant characteristics

#### 9 Setting
- **2 Points:** Description of general location and detailed description of the specific environment
- **1 Point:** Description of either general location or specific environment but details are sparse
- **0 Points:** Neither general location nor specific environment are described

#### 10 Dependent variable (target behaviour)
- **2 Points:** Target behaviour is operationally defined in precise terms and the method of measuring it is described
- **1 Point:** Target behaviour is operationally defined, but its description and/or method of measurement is not clear and precise
- **0 Points:** Target behaviour is not operationally defined

#### 11 Independent variable (therapy/intervention)
- **2 Points:** Detailed description of content of the intervention including any equipment/manuals (for medical use: title, content of the agents, both active and placebo) and 3 procedural details: number, duration (doseage for medical N=of-1) and frequency of sessions
- **1 Point:** General description of content of intervention (and equipment/manuals) and 2/3 procedural details (number, duration/dosage, frequency)
- **0 Points:** Intervention described in general terms; only identified as a treatment approach e.g., "cognitive-behaviour therapy"; <2/3 procedural details

#### 12 Raw data record
- **2 Points:** Raw data record with a data point for every session/observation period. If ≥10 individual trials, complete raw data record for ≥3 cases
- **1 Point:** If ≥10 or more individual trials, complete raw data record for ≥2 cases, or provision of a data record but data aggregated/averaged across sessions/periods, or provision of data record but a priori decision not to record data for every session (e.g., multiple probe studies)
- **0 Points:** No raw data reported; data only reported for selected phases, omitted data

#### 13 Data analysis
- **2 Points:** Systematic visual analysis with specified protocol, or visual analysis aided by quasi-statistical techniques, or statistical analysis with rationale
- **1 Point:** Systematic/aided visual analysis with selection of analytic techniques, or statistical analysis but no rationale, or a priori decision to the level of the target behaviour constituting an empirically derived clinically meaningful change
- **0 Points:** Visual inspection without data analysis; analysis not conducted on target behaviour; arbitrary selection of level of target behaviour

#### 14 Replication
- **2 Points:** 1 original + 3 replications (direct intersubject or systematic including settings, behaviours, practitioners, interventions)
- **1 Point:** 1 original + 1 or 2 replications (inter-subject or systematic)
- **0 Points:** No replication

#### 15 Generalisation
- **2 Points:** Specified generalisation measure is probed in spaced phase
- **1 Point:** Specified generalisation measure is probed in at least pre- and post-treatment phases
- **0 Points:** No generalisation measures

### Internal Validity subscale: ____ / ____ | External Validity and Interpretation subscale: ____ / ____ | Total score: ____ / ____
Appendix 2.1 The Single-Case Reporting guideline In BEhavioural interventions (SCRIBE) 2016 Checklist

<table>
<thead>
<tr>
<th>Item number</th>
<th>Topic</th>
<th>Item description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>TITLE and ABSTRACT</td>
<td>Identify the research as a single-case experimental design in the title</td>
</tr>
<tr>
<td>2</td>
<td>Abstract</td>
<td>Summarise the research question, population, design, methods including intervention/s (independent variable/s) and target behaviour/s and any other outcome/s (dependent variable/s), results, and conclusions</td>
</tr>
<tr>
<td>3</td>
<td>INTRODUCTION</td>
<td>Describe the scientific background to identify issue/s under analysis, current scientific knowledge, and gaps in that knowledge base</td>
</tr>
<tr>
<td>4</td>
<td>Aims</td>
<td>State the purpose/aims of the study, research question/s, and, if applicable, hypotheses</td>
</tr>
<tr>
<td>5</td>
<td>METHODS DESIGN</td>
<td>Identify the design (e.g., withdrawal/reversal, multiple-baseline, alternating-treatments, changing-criterion, some combination thereof, or adaptive design) and describe the phases and phase sequence (whether determined a priori or data-driven) and, if applicable, criteria for phase change</td>
</tr>
<tr>
<td>6</td>
<td>Procedural changes</td>
<td>Describe any procedural changes that occurred during the course of the investigation after the start of the study</td>
</tr>
<tr>
<td>7</td>
<td>Replication</td>
<td>Describe any planned replication</td>
</tr>
<tr>
<td>8</td>
<td>RANDOMISATION</td>
<td>State whether randomisation was used, and if so, describe the randomisation method and the elements of the study that were randomized</td>
</tr>
<tr>
<td>9</td>
<td>Blinding</td>
<td>State whether blinding/masking was used, and if so, describe who was blinded/masked</td>
</tr>
<tr>
<td>10</td>
<td>PARTICIPANT/S or UNIT/S</td>
<td>State the inclusion and exclusion criteria, if applicable, and the method of recruitment</td>
</tr>
<tr>
<td>11</td>
<td>Selection criteria</td>
<td>For each participant, describe the demographic characteristics and clinical (or other) features relevant to the research question, such that anonymity is ensured</td>
</tr>
<tr>
<td>12</td>
<td>CONTEXT</td>
<td>Describe characteristics of the setting and location where the study was conducted</td>
</tr>
<tr>
<td>13</td>
<td>APPROVALS</td>
<td>State whether ethics approval was obtained and indicate if and how informed consent and/or assent were obtained</td>
</tr>
<tr>
<td>14</td>
<td>MEASURES and MATERIALS</td>
<td>Operationally define all target behaviours and outcome measures, describe reliability and validity, state how they were selected, and how and when they were measured</td>
</tr>
<tr>
<td>15</td>
<td>Equipment</td>
<td>Clearly describe any equipment and/or materials (e.g., technological aids, biofeedback, computer programs, intervention manuals or other material resources) used to measure target behaviour/s and other outcome/s or deliver the interventions</td>
</tr>
<tr>
<td>16</td>
<td>INTERVENTIONS</td>
<td>Describe intervention and control condition in each phase, including how and when they were actually administered, with as much detail as possible to facilitate attempts at replication</td>
</tr>
<tr>
<td>17</td>
<td>Procedural fidelity</td>
<td>Describe how procedural fidelity was evaluated in each phase</td>
</tr>
<tr>
<td>18</td>
<td>ANALYSIS</td>
<td>Describe and justify all methods used to analyse data</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Sequence completed</td>
<td>For each participant, report the sequence actually completed, including the number of trials for each session for each case. For participant/s who did not complete, state when they stopped and the reasons.</td>
<td></td>
</tr>
<tr>
<td>Outcomes and estimation</td>
<td>For each participant, report results, including raw data, for each target behaviour and other outcome/s.</td>
<td></td>
</tr>
<tr>
<td>Adverse events</td>
<td>State whether or not any adverse events occurred for any participant and the phase in which they occurred.</td>
<td></td>
</tr>
<tr>
<td>Interpretation</td>
<td>Summarise findings and interpret the results in the context of current evidence.</td>
<td></td>
</tr>
<tr>
<td>Limitations</td>
<td>Discuss limitations, addressing sources of potential bias and imprecision.</td>
<td></td>
</tr>
<tr>
<td>Applicability</td>
<td>Discuss applicability and implications of the study findings.</td>
<td></td>
</tr>
<tr>
<td>Protocol</td>
<td>If available, state where a study protocol can be accessed.</td>
<td></td>
</tr>
<tr>
<td>Funding</td>
<td>Identify source/s of funding and other support; describe the role of funders.</td>
<td></td>
</tr>
</tbody>
</table>
Appendix 2.2 Letter of Invitation to Study

MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

My name is Claire McGoldrick and I am a trainee Clinical Psychologist. I would like to invite you to take part in a research study which is exploring whether a mobile application called MindMate is effective at helping people with a diagnosis of dementia to remember to carry out everyday tasks.

The study aims to explore this application with people who are considered to be in the early stages of dementia, together with their carer. For the first few weeks of the study you and your carer will simply record how often you forget to do things that you have noticed are difficult to remember. This will take between five and seven weeks.

Then MindMate will be downloaded to your phone or tablet and it will provide reminders about things to do. These reminders will be chosen by you and your carer at the beginning of each week, for a period of five weeks. You will also be invited to your nearest clinic or, with your permission, the researcher can visit you at home to complete a small number of cognitive assessments. However, if you have already completed these tests with your Community Mental Health Team psychologist you will not need to do them again. You will be asked to attend the clinic or receive a home visit (according to your preference) once a week for the duration of the study. These should last approximately twenty minutes, and will provide us with an
opportunity to see how you are getting on, and answer any questions you might have.

It is hoped that this study will provide evidence as to whether this memory aid could be useful for individuals with a diagnosis of dementia who report memory difficulties.

If you would like further information about this study, please complete the slip below and hand it to your health care worker. The researcher will then be in touch to provide more information to help you decide if you would like to participate.

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**MindMate: A Study of a Reminder System for People with Dementia**

I would like to find out more about this study and I can be contacted on the details below by the researcher:

Name: ____________________________________________________________

Address:

_________________________________________________________________

_________________________________________________________________

Telephone number: _________________________________________________
MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

Participant Information Sheet

I would like to invite you to take part in a research study. Before you decide, you need to understand why the research is being done and what it would involve for you. Please take time to read the following information carefully. If anything is unclear or you would like more information please contact me. All relevant contact details are at the bottom of this leaflet.

Who is conducting the research?
The research is being carried out by Claire McGoldrick (Trainee Clinical Psychologist), from the Institute of Health & Wellbeing at the University of Glasgow. I am studying for my Clinical Psychology Doctorate and I am conducting this research to fulfil the requirements of the course. I also have a keen interest in dementia and interventions that aim to support people with the diagnosis.

What is the purpose of the study?
People with a diagnosis of dementia often report difficulties with their memory. This study aims to assess whether a mobile application (app) called MindMate is effective at helping people with the diagnosis to remember to carry out everyday tasks.

Why have I been invited?
You have been invited to take part in this study because you have recently received a diagnosis of dementia, which is considered to be in the early stages.
Do I have to take part?
NO. It is entirely up to you to decide. You will be asked to sign a consent form to show you have agreed to take part. However, you are free to withdraw at any time, without giving reason. If you decide to withdraw from the study, this would not affect any care you or your carer are currently receiving.

What does taking part involve?
You will be invited to attend the clinic or receive a home visit for a couple of hours to complete some cognitive assessments. However, if you have already completed these tests with your Community Mental Health Team psychologist you will not need to do them again, we will record the results of these tests from your medical records instead. The researcher will look at this will help us to develop a clearer picture of your current difficulties.

Following this, a ‘baseline’ period will take place. This will be randomised for each participant and will occur for 5-7 weeks. Randomisation involves using a computer program to randomly assign you to a baseline period of 5, 6 or 7 weeks. Together with your carer you will first identify the tasks that you are having difficulty remembering in your everyday life. Your carer will then be sent a weekly monitoring form, which they will use each day to note whether or not you have remembered to complete the task. A text reminder will be sent to your carer’s phone reminding them to complete this form.

Following this initial baseline period, you will be invited back into the clinic or receive a home visit for approximately one hour. During this visit, you will receive an introduction to MindMate, which has been specifically designed for use by people with dementia, and a demonstration of the reminder tool on the MindMate app. This will involve sending reminder alerts to your smart phone or tablet. A week of practice using the application on your smart phone or tablet will take place before the next stage of the study.
The next phase will then take place for 5 weeks and during this time you will receive a reminder prompt from MindMate for each task that you need to remember. Your carer will monitor which tasks you completed following the reminder prompt, and those you did not, on the weekly monitoring form. This will allow us to see whether using MindMate makes it more likely that tasks will be completed.

At the end of the study, you will be invited back to participate in a final clinical interview, lasting approximately one hour. This will provide you with the opportunity to feedback how you got on with the app and to complete the post intervention questionnaire. Some of this interview will be recorded. Any direct quotes used in the write up of this research will be anonymised.

Both you and your carer will be asked to complete a consent form prior to commencing the study. You will receive a copy of your signed consent to keep.

**What happens to the information?**

Your identity and personal information will be completely confidential and known only to the researcher and her supervisors (Dr Stephanie Crawford and Professor Jonathan Evans). A representative of the study sponsor, NHS Greater Glasgow and Clyde may also look at this information, to make sure the study is being conducted correctly. All confidential information will be stored within a locked filing cabinet. The data will be held in accordance with the Data Protection Act, which means they are kept safely. Personal information will not be revealed to other people without your permission.

In rare circumstances, confidentiality may have to be breached. This is in cases where the researcher becomes concerned for the safety of the participant or others. The participant will be informed prior to doing so.
What are the possible benefits of taking part?
It is hoped that by taking part in this research, you will be providing valuable information regarding how useful mobile apps are in supporting people with a dementia, who report memory difficulties. Should the intervention prove effective for you, you can continue to use the app following completion of the study. Training on using the app and using other tools within the app will also be offered by the co-founders of the MindMate app in the phase of the study when you are using MindMate.

What are the possible disadvantages and risks of taking part?
Your test results could indicate that your difficulties such as memory have become worse over time. In this instance, additional support can be provided by contacting your healthcare provider who may arrange a review or additional support measures for you. The researcher will be happy to help you with this if required. It will be helpful for your GP to be aware of the results of the tests and therefore if you give your permission we will inform your GP that you have participated and pass on the test results. This study will require your commitment for 11-13 consecutive weeks.

Who has reviewed the study?
This study has been reviewed by the NHS West of Scotland Research Ethics Committee and the University of Glasgow.

If you have any further questions?
You will have a copy of the information sheet and signed consent form to keep. If you would like further information about this research project please contact Claire McGoldrick or her clinical supervisor Dr Stephanie Crawford. If you wish to seek general advice about participating in this study from someone not closely linked to the study, please contact Professor Tom McMillan. Please find all contact details overleaf.
Contacts:
Ms Claire McGoldrick
Trainee Clinical Psychologist
Institute of Health and Wellbeing
Gartnavel Royal Hospital
1055 Great Western Road
G12 0XH
Tel: 0141 211 0607
Email: c.mcgoldrick.1@research.gla.ac.uk

Dr Stephanie Crawford
Consultant Clinical Psychologist
Inverclyde Older People CMHT
Crown House
30 King Street
Greenock
PA15 1NL
Tel: 01475 558045
Email: Stephanie.Crawford@ggc.scot.nhs.uk

Professor Jonathan Evans
Professor of Applied Neuropsychology
Mental Health and Wellbeing
University of Glasgow
The Academic Centre
Gartnavel Royal Hospital
1055 Great Western Road
Glasgow
G12 0XH
Tel: 0141 211 0694
Email: jonathan.evans@glasgow.ac.uk

Professor Tom McMillan
Professor of Clinical Neuropsychology
Mental Health and Wellbeing
University of Glasgow
The Academic Centre
Gartnavel Royal Hospital
1055 Great Western Road
Glasgow
G12 0XH
Tel: 0141 211 0354
Email: Thomas.McMillan@glasgow.ac.uk

If you have a complaint about any aspect of the study?
If you are unhappy about any aspect of the study and wish to make a complaint, please contact the researcher in the first instance. The normal NHS complaint mechanisms are also available to you.

Thank-you for your time
Partner Information Sheet

I would like to invite you to take part in a research study. Before you decide, you need to understand why the research is being done and what it would involve for you. Please take time to read the following information carefully. If anything is unclear or you would like more information please contact me. All relevant contact details are at the bottom of this leaflet.

Who is conducting the research?
The research is being carried out by Claire McGoldrick (Trainee Clinical Psychologist), from the Institute of Health & Wellbeing at the University of Glasgow. I am studying for my Clinical Psychology Doctorate and I am conducting this research to fulfil the requirements of the course. I also have a keen interest in dementia and interventions that aim to support people with a diagnosis of dementia.

What is the purpose of the study?
People with a diagnosis of dementia often report difficulties with their memory. This study aims to assess whether a mobile application (app) called MindMate is effective at helping people with a diagnosis of dementia to remember to carry out everyday tasks.

Why have I been invited?
You have been invited to take part in this study because you are the partner/family member of someone who has received this diagnosis.
Do I have to take part?
NO. It is entirely up to you to decide. You will be asked to sign a consent form to show you have agreed to take part. However, you are free to withdraw at any time, without giving reason. If you decide to withdraw from the study, this would not affect any care you or your partner are currently receiving.

What does taking part involve?
As a carer, you will initially be invited to participate in an interview, along side your partner/family member, with the main researcher. This will last approximately an hour and take place in the clinic or at your home, and will involve answering questions about the difficulties your partner/family member currently faces. This will help us to develop a clearer picture of their current difficulties.

Following this, a ‘baseline’ period will take place. The length of this period will be randomised across all participants, lasting for 5, 6, or 7 weeks. Together with your partner or family member you will first identify the tasks that they are having difficulty remembering and completing in their everyday life (e.g. missed appointments). You will then be sent a weekly monitoring form, which you will use each day to note whether or not your partner/family member remembered to complete the task. A daily text reminder will be sent to your phone reminding you to complete this form.

Following this initial baseline period, your partner/family member will be invited back into the clinic or receive a home visit for approximately one hour. During this visit, they will receive an introduction to MindMate, which has been specifically designed for use by people with dementia, and a demonstration of the reminder tool on the MindMate app. This will involve sending reminder alerts to their smart phone or tablet. A week of practice using the application on their smart phone or tablet will take place before the next stage of the study.
The next phase will then take place for 5 weeks and during this time they will receive a reminder prompt from MindMate for each task that they need to remember. You will monitor which tasks they completed following the reminder prompt, and those they did not, on the weekly monitoring form. This will allow us to see whether using MindMate makes it more likely that tasks will be completed.

Both you and your partner/family member will be asked to complete a consent form prior to commencing the study. You will receive a copy of your signed consent to keep.

**What happens to the information?**
Your identity and personal information will be completely confidential and known only to the researcher and her supervisors (Dr Stephanie Crawford and Professor Jonathan Evans). A representative of the study sponsor, NHS Greater Glasgow and Clyde may also look at this information, to make sure the study is being conducted correctly. The information obtained will remain confidential and stored within a locked filing cabinet within the University of Glasgow. The data will be held in accordance with the Data Protection Act, which means they are kept safely. Personal information will not be revealed to other people without your permission.

**What are the possible benefits of taking part?**
It is hoped that by taking part in this research, you will be providing valuable information regarding how useful mobile apps are in supporting people with a dementia, who report memory difficulties. Should the intervention prove effective for your partner/family member, they can continue to use the app following completion of the study. Training on using the app and using other tools within the app will also be offered by the co-founders of the MindMate app in the phase of the study when your partner/family member is using MindMate.
What are the possible disadvantages and risks of taking part?
Your partner/family member’s test results could indicate that their difficulties such as memory have become worse over time. In this instance, additional support can be provided by contacting your healthcare provider who may arrange a review or additional support measures. The researcher will be happy to help you with this if required. It will be helpful for your partner/family member’s GP and Community Mental Health Team to be aware of the results of their tests and therefore if they give their permission we will inform them that they have participated and pass on the test results. This study will require your commitment for 11-13 consecutive weeks.

Who has reviewed the study?
This study has been reviewed by the NHS West of Scotland Research Ethics Committee and the University of Glasgow.

If you have any further questions?
You will have a copy of the information sheet and signed consent form to keep. If you would like further information about this research project please contact Claire McGoldrick or her clinical supervisor Dr Stephanie Crawford. If you wish to seek general advice about participating in this study from someone not closely linked to the study, please contact Professor Tom McMillan. Please find all contact details overleaf.

Contacts:
Ms Claire McGoldrick
Trainee Clinical Psychologist
Institute of Health and Wellbeing
Gartnavel Royal Hospital
1055 Great Western Road
G12 0XH
Tel: 0141 211 0607
Email: c.mcgoldrick.1@research.gla.ac.uk
Dr Stephanie Crawford  
Consultant Clinical Psychologist  
Inverclyde Older People CMHT  
Crown House  
30 King Street  
Greenock  
PA15 1NL  
Tel: 01475 558045  
Email: Stephanie.Crawford@ggc.scot.nhs.uk

Professor Jonathan Evans  
Professor of Applied Neuropsychology  
Mental Health and Wellbeing  
University of Glasgow  
The Academic Centre  
Gartnavel Royal Hospital  
1055 Great Western Road  
Glasgow  
G12 0XH  
Tel: 0141 211 0694  
Email: jonathan.evans@glasgow.ac.uk

Professor Tom McMillan  
Professor of Clinical Neuropsychology  
Mental Health and Wellbeing  
University of Glasgow  
The Academic Centre  
Gartnavel Royal Hospital  
1055 Great Western Road  
Glasgow  
G12 0XH  
Tel: 0141 211 0354  
Email: Thomas.McMillan@glasgow.ac.uk
If you have a complaint about any aspect of the study? If you are unhappy about any aspect of the study and wish to make a complaint, please contact the researcher in the first instance. The normal NHS complaint mechanisms are also available to you.

Thank-you for your time
CONSENT FORM

Title of Project: MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

Name of researcher: Claire McGoldrick

Participant Identification number for this Trial: Please Initial Box

1. I confirm that I have read and understand the information sheet (version 2 08/09/2016) for the above study.

2. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

3. I understand that my participation is voluntary and that I am free to withdraw at any time without given any reason.

4. I understand that information from the questionnaires I complete will be kept strictly confidential, and any information about me will have my personal details removed so that I cannot be recognised.

5. I consent to my G.P being informed of my participation in this study.

6. I consent to the use of quotations from interviews. Any quotes used from clinical interviews will be anonymised.

7. I consent to the researcher retrieving the data on my neuropsychological assessment from my medical file.

8. I understand that relevant sections of my care record and data collected during the study may be looked at by responsible individuals from the sponsor or host organisation or from regulatory authorities where it is relevant to taking part in this research.

9. I agree to take part in this study.
Name of Participant  Date:
Signature:

Name of Person Taking Consent  Date:
Signature:
CONSENT FORM – PARTNER/FAMILY MEMBER

Title of Project: MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

Name of researcher: Claire McGoldrick

Participant Identification number for this Trial: Please Initial Box

1. I confirm that I have read and understand the information sheet (version 2 08/09/2016) for the above study.

2. I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.

3. I understand that my participation is voluntary and that I am free to withdraw at any time without given any reason.

4. I understand that information from the interviews I complete will be kept strictly confidential, and any information about me will have my personal details removed so that I cannot be recognised.

5. I understand that a representative from the study sponsor, NHS GG&C, may look at information from the study for audit purposes. I understand that this information will be kept strictly confidential.

6. I agree to take part in this study.

Name of Participant Date: Signature:

Name of Person Date: Taking Consent Signature:
### Appendix 2.5 Weekly Monitoring Form

**Monitoring Form**

Week Beginning: ________________

<table>
<thead>
<tr>
<th>Day of the Week</th>
<th>Target to be Remembered</th>
<th>Time due to be completed by:</th>
<th>Completed without prompting? Please ✓/✗*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuesday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wednesday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thursday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Friday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Saturday</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* ✓ if completed independently or ✗ if forgotten/ prompting require*
Appendix 2.6 NHS Ethics & SSA Letters

WoSRES
West of Scotland Research Ethics Service

West of Scotland REC 3
West of Scotland Research Ethics Service
West Glasgow Ambulatory Care Hospital
Darnair Street
Glasgow
G3 8SW

Date: 07 November 2016
Direct line: 0141 232 1904
E-mail: WoSREC3@ggc.scot.nhs.uk

Please note: This is an acknowledgement letter from the REC only and does not allow you to start your study at NHS sites in England until you receive HRA Approval.

Dear Professor Evans,

Study title: MindMate: A Single Case Experimental Design study of a Reminder System for People with Mild Dementia
REC reference: 16WS/0219
IRAS project ID: 204924

Thank you for your response of 4 November 2016. I can confirm the REC has received the documents listed below and that these comply with the approval conditions detailed in our letter dated 03 November 2016.

Documents received

The documents received were as follows:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participant consent form [v3.4.11.2016]</td>
<td>3</td>
<td>04 November 2016</td>
</tr>
<tr>
<td>Participant information sheet (PIS) (Participant VS 16.02.2016)</td>
<td>5</td>
<td>04 November 2016</td>
</tr>
</tbody>
</table>

Approved documents

The final list of approved documentation for the study is therefore as follows:

<table>
<thead>
<tr>
<th>Document</th>
<th>Version</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>GP/consultant information sheets or letters [v4.8.09.2016]</td>
<td>4</td>
<td>08 September 2016</td>
</tr>
<tr>
<td>Document</td>
<td>Version</td>
<td>Date</td>
</tr>
<tr>
<td>-------------------------------------------------------------------------</td>
<td>---------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Interview schedules or topic guides for participants [Interview Schedule 5.9.2016]</td>
<td>1</td>
<td>08 September 2016</td>
</tr>
<tr>
<td>Letters of invitation to participant [V3 08/07/2016]</td>
<td>3</td>
<td>08 July 2016</td>
</tr>
<tr>
<td>Non-validated questionnaire [Pre UTAUT]</td>
<td>4</td>
<td>16 September 2016</td>
</tr>
<tr>
<td>Non-validated questionnaire [Post UTAUT]</td>
<td>3</td>
<td>16 September 2016</td>
</tr>
<tr>
<td>Participant consent form [Carer V3 18.05.2016]</td>
<td>3</td>
<td>16 September 2016</td>
</tr>
<tr>
<td>Participant information sheet (PIS) [Carer V2 8.09.2016]</td>
<td>2</td>
<td>08 September 2016</td>
</tr>
<tr>
<td>REC Application Form [REC_Form_0710.2016]</td>
<td></td>
<td>07 October 2016</td>
</tr>
<tr>
<td>Research protocol or project proposal [Research Proposal V2 7.09.16]</td>
<td>2</td>
<td>07 September 2016</td>
</tr>
<tr>
<td>Response to Additional Conditions Met [No letter was received]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary CV for Chief Investigator (Ch) [CV 6.07.2016]</td>
<td></td>
<td>10 March 2016</td>
</tr>
<tr>
<td>Summary CV for student (CV 23.09.2016)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Summary CV for supervisor (student research) [CV 15.9.2016]</td>
<td>2</td>
<td>15 September 2016</td>
</tr>
<tr>
<td>Summary, synopsis or diagram (flowsheet) of protocol in non-technical language [Method Flow Diagram V1 04.10.2016]</td>
<td>1</td>
<td>04 October 2016</td>
</tr>
<tr>
<td>Validated questionnaire [Rivermead BMT]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [Trails]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [Test of Pro Morbid Functioning]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [Prospective and Retrospective Memory Questionnaire]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [Fluency Tests]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [PRMQ-Carer]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Validated questionnaire [WASI II]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

You should ensure that the sponsor has a copy of the final documentation for the study. It is the sponsor's responsibility to ensure that the documentation is made available to R&D offices at all participating sites.

16/WS/0219 Please quote this number on all correspondence

Yours sincerely,

R. Gallacher
Assistant Administrator

Copy to: Ms Emma-Jane Gault
         Ms Joanne McGarry, NHS Greater Glasgow and Clyde
NHS GG&C Board Approval

Dear Ms. McGoldrick,

Study Title: MindMate: A Single Case Experimental Design study of a Reminder System for People with Mild Dementia
Principal Investigator: Clare McGoldrick
GG&C HB site: NHS Greater Glasgow & Clyde
Sponsor: University of Glasgow/NHS Greater Glasgow & Clyde
R&D reference: G10NE538
REC reference: 16/WS/0219
Protocol no: V2 07/09/2016

I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant overall governance and management approval for the above study.

At the point of this management approval, R&D has received confirmation of Head of Department approval for Glenkirk OPCMHT and Belmont OPCMHT. It is the responsibility of the investigator to approach individual heads of any additional study sites to negotiate access for patient recruitment. Any additional sites participation is entirely at the discretion of the unit/department head and R&D should be updated when additional HOD approvals are sought.

Conditions of Approval

1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial Regulations, 2004
   a. During the life span of the study GGHB requires the following information relating to this site
      i. Notification of any potential serious breaches.
      ii. Notification of any regulatory inspections.

   It is your responsibility to ensure that all staff involved in the study at this site have the appropriate GCP training according to the GGHB GCP policy (www.nhsggc.org.uk/content/default.asp?page=1411), evidence of such training to be filed in the site file.

2. For all studies the following information is required during their lifespan.
   a. Recruitment Numbers on a quarterly basis
   b. Any change of staff named on the original DSI form
   c. Any amendments – Substantial or Non Substantial
   d. Notification of Trial study ending and final recruitment figures
   e. Final Report & Copies of Publications/Abstracts

Please add this approval to your study file as this letter may be subject to audit and monitoring.

Your personal information will be held on a secure national web-based NHS database.

I wish you every success with this research study.

83
Yours sincerely,

[Signature]

Joanne McGarry  
Research Co-ordinator
Appendix 2.7 MindMate Tutorial Presentation

On your iPhone or iPad, click on the MindMate app and open it through this action.

Being in the app, click on "Reminders".

You are now in the reminder section of your iPad or iPhone.

Click on "Add Reminder".
Adding a reminder is just 4 steps away

Step 1: click on the field "I want to be reminded of" and type in the purpose of your reminder. E.g. "Call Claire"

Step 2: select the day via "select day" OR the calendar function under "I want to be reminded of"

Step 2: select the time via "Select Time" —> Pay attention to AM vs. PM
Step 4: tap on “Tap here to Add Reminder” via Final Step —> the reminder will be added to the first screen.
MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia

Pre-Intervention Questionnaire

The following questionnaire is adapted from the Unified Theory of Acceptance and Use of Technology (UTAUT) and attempts to develop an understanding of your intentions to use assistive technology and subsequent usage behaviour.

Please answer each question by circling the number which best reflects how you feel about the statement provided. Answers range from 1 (Strongly Agree) to 5 (Strongly Disagree).

I think the MindMate Reminder will be useful for remembering everyday tasks

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

Using the MindMate Reminder will enable me to accomplish tasks at the right time

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

Using MindMate Reminder will help me get more things done than usual

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>
### MindMate Reminder will be clear and understandable

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### It will be easy for me to become skilful at using MindMate Reminder

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### I will find MindMate Reminder easy to use

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### Learning to operate MindMate Reminder will be achievable for me

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### Using MindMate Reminder is a great idea

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### Working with MindMate Reminder will be fun

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>
**I will like working with MindMate Reminder**

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**People who are important to me think that I should use MindMate Reminder**

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**I have the knowledge necessary to use MindMate Reminder**

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**I will be able to complete a job/task using MindMate reminder**

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**I feel apprehensive about using MindMate Reminder**

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>

**It worries me to think that I could lose a lot of information using MindMate Reminder by hitting the wrong key**

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td></td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>
I hesitate to use MindMate Reminder for fear of making mistakes I cannot correct

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

I intend to use MindMate Reminder following completion of the current study

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

Thank you for completing this questionnaire
**MindMate: A Single Case Experimental Design Study of a Reminder System for People with Dementia**

**Post-Intervention Questionnaire**

The following questionnaire is adapted from the Unified Theory of Acceptance and Use of Technology (UTAUT) and attempts to develop an understanding of your intentions to use assistive technology and subsequent usage behaviour.

Please answer each question by circling the number which best reflects how you feel about the statement provided. Answers range from 1 (Strongly Agree) to 5 (Strongly Disagree).

### I find the MindMate Reminder useful for daily tasks.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### Using the MindMate Reminder enables me to accomplish tasks at the right time

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

### Using MindMate Reminder helps me get more things done than usual

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Statement</td>
<td>Strongly Agree</td>
<td>Agree</td>
<td>Neither Agree or Disagree</td>
<td>Disagree</td>
</tr>
<tr>
<td>---------------------------------------------------------------------------</td>
<td>----------------</td>
<td>-------</td>
<td>---------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>MindMate Reminder is clear and understandable.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>It will be easy for me to become skilful at using MindMate Reminder.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I find MindMate Reminder easy to use.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Learning to operate MindMate Reminder is achievable for me.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Using MindMate Reminder is a great idea.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Working with MindMate Reminder is fun.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
I like working with MindMate Reminder.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

People who are important to me think that I should use MindMate Reminder

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

I have the knowledge necessary to use MindMate Reminder.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

I could complete a job/task using MindMate Reminder

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

I feel apprehensive about using MindMate Reminder.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

It's worries me to think I could lose a lot of information using MindMate Reminder by hitting the wrong key.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>
I hesitate to use MindMate Reminder for fear of making mistakes I cannot correct.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

I intend to use MindMate Reminder in the next 3 months.

<table>
<thead>
<tr>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree or Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

Thank you for completing this questionnaire
Appendix 2.9 Visual Analysis of Participants

Within-condition and between-condition analysis of graphed data. The three graphs summarise the data of the three participants, respectively. The data points represent the percentage of target memory tasks completed each week in each study phase (A = baseline, B = intervention). The Y axis shows percent performance and X axis shows study week.

All data points located between the dashed black line are considered within the stability envelope.

**Participant FD**

![Graph for Participant FD]

**Participant SI**

![Graph for Participant SI]
Participant CE
MindMate: A Single Case Experimental Design Study in People with Mild Dementia

Name of Assessment: Course 8 Major Research Project
Matriculation Number: 2166409m
University Supervisor: Professor Jonathon Evans
Field Supervisor: Dr. Stephanie Crawford
Version: 2
Date of Submission: 7th of September 2016
Word Count: 4,099
Abstract

Research into the effectiveness of electronic devices such as memory aids remains limited in individuals with a diagnosis of dementia. Mindmate is a recently developed mobile application that aims to support individuals with a diagnosis of dementia, improving self-management skills and quality of life. A single case experimental design multiple baseline across participants study will be used to explore the effectiveness of MindMate reminder alerts delivered to a smartphone or tablet computer as a memory aid.

Three participants with a diagnosis of dementia, who are considered to be in the early stages and who report everyday prospective memory difficulties, will be recruited. A multiple baseline across participants design will be incorporated, and will include a baseline phase that will last between five to seven weeks, followed by a five-week intervention phase where MindMate is used. Target memory behaviours will be identified prior to the intervention phase, and family members or carers will monitor their success.

Results will be analysed using visual inspection and Tau-U analysis.
Introduction

Background

According to Alzheimer’s Scotland there are approximately 90,000 people living with dementia in Scotland (Alzheimer’s Scotland Action on Dementia, 2015). With improved healthcare and better standards of living people are living longer, which for Scotland means that the number of people with dementia is expected to double between 2011 and 2031 (Patch, 2015). Dementia remains one of the foremost public health challenges within the country, with current costs estimated at £1.7 billion per annum and dementia caregivers reported to be more burdened and more vulnerable to health problems than other caregiver groups (Schulz & Martire, 2004, Sussman & Regehr, 2009).

While there is currently no cure available for dementia, interventions have focused on improving independence and quality of life. As a result, increasing emphasis has been placed on the early diagnosis of dementia to enable those affected to access early interventions and treatments, as well as for accessing practical information, advice and support (Alzheimer’s Society, 2013). Appropriate support can have a significant impact on the degree to which someone is able to manage their condition over time and live independently, delaying the need for care home or hospital admission, which ultimately adds savings to the health economy (Department of Health, 2009).

Assistive Technology

Memory difficulties reported among those with a diagnosis of dementia not only include the ability to recall past information, but also the ability to remember to do something at a specific time and place in the future (Prospective memory) (Dewar, Kopelman, Kapur & Wilson, 2015). A range of memory aids currently exist, with the potential to be highly effective in the compensation of memory problems. In their systematic review and meta-analysis, Jamieson, Cullen, McGee-Lennon, Brewster & Evans (2013) noted that evidence supports use of Assistive Technology (AT) for reminding, however noted the dearth of investigations into their use amongst people with degenerative diseases.

Compensatory approaches to memory impairment aim to bypass the deficit area and teach the individual strategies to solve functional problems (Kapur and Wilson, 2009). Mastering
these strategies will, it is assumed, help the individual manage in their everyday environment despite the presence of the impairment (O’Neill & Gillespie, 2015).

External memory aids are the most widely used and effective intervention for assisting memory difficulties and include various devices such as personal hand-held computers, e.g., mini notebooks and tablets, such as the iPad, mobile phones and smartphones. Various electronic aids have been shown to aid prospective memory, including the NeuroPage and Personal Digital Assistant (PDA) (e.g. Wilson, Emslie, Quirk & Evans, 2001; Gentry, Wallace, Kvarfordt, & Lynch, 2008). Jamieson et al., (2013) suggest that memory aids may support learning of associations (e.g. taking medication and mealtimes). This highlights the importance of learning to use an aid while the cognitive impairment is relatively mild; this knowledge is more likely to be retained as a person deteriorates.

Mobile applications (Apps), computer programs that run on mobile devices such as smartphones and tablet computers, offer an alternative solution to overcoming the cost associated with the use of technological memory aids, if the individual already owns a smartphone/tablet. In a study of people with an acquired brain injury, McDonald, Haslam, Yates, Gurr, Leeder, & Sayers et al., (2011) conducted a small randomised controlled trial using the Google Calendar application, in which participants recorded completion of prospective memory tasks. After event details are recorded, Google calendar sends timed reminders to the person’s mobile phone. In their study, McDonald et al., (2011) found Google Calendar to be significantly more effective than a paper-based diary. While all participants in this study had prior experience in the use of memory aids, a more recent single case experimental design study tested its use on an individual who had severe verbal and visual memory difficulties and no prior use of a memory aid (Baldwin and Powell, 2015). Their study showed a reduction in forgetting in chosen target behaviours, with the participant also reporting improvements in memory.

More recently, a dementia specific application called MindMate (2015) was developed, with the aim of supporting users in their everyday lives, improving self-management skills, and therefore maintaining the independence of users for as long as possible. This application includes a reminding tool similar to the one on Google Calendar. Mindmate also offer two other versions of the app, Mindmate Pro and Mindmate Plus. The Mindmate Pro version is intended for care homes and allows more than one individual profile to be created on the
one app. Mindmate Plus allows remote access for carers who may wish to enter information (e.g. Reminders) for the individual with dementia from their own phone/tablet.

Aims and hypotheses

The present study aims to examine the use of MindMate as a memory aid for adults who have received a diagnosis dementia, who are considered to be in the early stages, and who are specifically experiencing memory and executive functioning difficulties.

The main hypothesis is:

Performance on target memory tasks will improve significantly with the introduction of MindMate reminding tool.

Plan of Investigation

Participants

Three participants, aged 18 years or above and who have received a diagnosis of mild dementia, will be recruited from Community Mental Health teams within the Greater Glasgow and Clyde Health board. All three participants will have been given a diagnosis by a psychiatrist using ICD-10 criteria. They will be reporting memory difficulties which have been confirmed by a professional or family member. They will also own a smart phone or tablet computer with internet, and have a family member/carer willing to support and monitor memory aid use.

Exclusion criteria will be participants who:

- have a pre-existing neurological or severe psychiatric problem (e.g. bipolar disorder, psychosis)
- have a diagnosis of dementia, considered to be in the moderate to severe stages
- have visual or auditory difficulties (which cannot be corrected with the use of glasses or hearing aids) that would prevent use of a smartphone;
- those whose first language is not English;
- have a diagnosed or suspected developmental learning disability;
- are currently using online or electronic memory aids. Previous memory aid use will be documented but will not exclude individuals from participation.
Neuropsychological data will be used to confirm that participants are presenting with some
degree of cognitive impairment. This will be gathered using the:

- Test of Pre-Morbid Functioning (TOPF, Wechsler, 2011);
- Rivermead Behavioural Memory Test - 3rd version (RBMT-3; Wilson, Greenfield,
  Clare, Baddeley, Cockburn, Watson, et al., 2008);
- Wechsler Abbreviated Scale of Intelligence – 2nd edition (WASI-II; Wechsler,
  1999);
- Trails subtest of the Delis–Kaplan Executive Function System (D-KEFS; Delis,
  Kaplan, & Kramer, 2001);
- Controlled Oral Word Association Test using letters F-A-S (Spreen & Benton,
  1977);
- Prospective and Retrospective Memory Questionnaire (Smith, Della Sala, Logie, &
  Maylor, 2000).

Neuropsychological assessment is often, although not always, used in the diagnostic
process of dementia. Therefore, some of the participants may have already completed these
assessments. In cases where they have not completed the tests, or they have not completed
all of the tests, the main researcher will administer the tests prior to beginning the
baseline phase of the study.

**Recruitment Procedures**

Potential participants will be given written information about the study via a member of the
Older People Community Mental Health Team or post diagnostic service they are known to,
within Greater Glasgow and Clyde. If interested, they will be provided with further written
information and they will complete an opt-in slip, consenting to be contacted, which will be
sent to the researcher. The researcher will contact the potential participants who will be
provided with the opportunity to discuss the study further and ask questions. If potential
participants agree to participate, they will be asked to sign a consent form. All information
provided will be in size 16 font to ensure ease of reading for those with visual impairments.
If more than three participants declare interest, those who have indicated interest first will
be recruited with a reserve list for any surplus. Should one or more of the three participants
drop out of the study, those on the reserve list will replace them.
Materials

Mindmate, Mindmate Pro and Mindmate Plus are free to download and use dementia applications. Mindmate includes a “Reminder” tool which allows events to be entered for a specific time and date, then sends reminder alerts about the event, thus acting as a memory prompt. Each participant will use their own phone/tablet as they will already be familiar with its use.

A weekly monitoring form listing individual prospective memory targets and the times they need to be completed will be provided to the carer/family member. Baldwin and Powell (2014) highlighted the importance of picking memory targets that were personally meaningful for the individual therefore memory targets will be constructed in conjunction with the participant and the carer. These will be causing the most disruption in the participants’ daily lives. This form can be used daily by an identified family member/carer to record whether or not activities were remembered and completed at an appropriate time. They will be asked to tick targets achieved without prompting from other people, and cross targets that were either forgotten, remembered but not completed, completed at the wrong time, or only completed following prompting from carer.

Design

A randomised single case experimental design (SCED) multiple baseline across participants study will be used, staggering the onset of the intervention. The three participants will be randomly allocated to a 5, 6 or 7-week baseline using the Research Randomizer programme provided by the Social Psychology Network (http://www.randomizer.org). MindMate will then be introduced for all three participants for a 6-week period. Withdrawing intervention might raise ethical issues, therefore a multiple baseline, as opposed to a withdrawal (e.g. ABA) design is more appropriate.

The study was developed with reference to the methodological quality criteria for single case experimental design studies (Risk of Bias in N of 1 trials – RoBiN-T, Tate, Perdices, Rosenketter, Wakim, Godbee, Togher & McDonald, 2013).
Procedure

Written information given to potential participants via Older People’s Community Mental Health Team (OPCMHT) or Post Diagnostic Support Service (PDS-S)

If participants express interest, further written information will be provided with opt in slip to be completed

Researcher contacts potential participants by phone to answer any questions relating to study

Participants and carers invited to clinic or to receive a visit at home to sign consent forms and complete clinical interview

Baseline phase (Weeks 1-5/6/7)
- Carers will be given weekly monitoring forms for the 5-7 week block
- A text reminder will be sent to the carer each day reminding them to complete the monitoring form
- Researcher will contact carer by phone once a week to answer any potential questions/comments

Pre-intervention phase (1 week)
Participants will be sent MindMate Reminders asking them to complete a numbers of tasks

Intervention phase (5 weeks)
- Researcher will meet with participant and carer once a week in their local OPCMHT or in their home for approx. 20 minutes
- During this visit, researcher will be informed of reminders that need to be set for the week ahead
- Any questions/comments can also be answered
- Reminders will then be sent to participants’ tablet/smart phone and completion will be recorded on the monitoring form

End of Intervention – Follow up Clinical Interview and completion of Post-Intervention questionnaire

Opt in Slip not completed – no further action
Excess participants will be placed on reserve list
Individual decides against further participation– no further action
Neuropsychological tests will then be completed, if not already done so
Participants are free to withdraw at any phase. Reasons for withdrawal will be noted, and further participants will be recruited from reserve list
MindMate training will run concurrently during 3 out of 5 weeks of the intervention phase

Participants are free to withdraw at any phase. Reasons for withdrawal will be noted, and further participants will be recruited from reserve list.
Ethical approval will be obtained from NHS Greater Glasgow and Clyde Ethics Committee. Informed consent will also be obtained from all three participants and their carers.

An initial interview with the participant and a family member/carer will identify target behaviours as well as previous memory aid use. This will be followed by approximately two hours of neuropsychological assessment in order to obtain quantitative data related to their cognitive difficulties. If data from these tests is available from routine assessment within the previous six months, these data will be used instead.

Baseline data will then be gathered over a period of time of 5-7 weeks, during which all target events that were forgotten as well as instances of reminding will be recorded. As in the Baldwin and Powell (2015) study a text message reminder will be sent to the carer every day (time of day to be pre-determined) to remind them to make the recording.

Immediately following baseline data collection, there will be week before intervention recording begins to familiarise each participant with the process involved. Part of this training process will include sending each participant reminders asking them to undertake a number of tasks (e.g. making a phone call to arrange an appointment). Intervention will then take place for 5 weeks.

At the beginning of each week of the intervention, the researcher will meet with the carer and participant in their local OPCMHT or in their home. They will be asked about upcoming events for the week which will be entered into MindMate by the researcher. The participant will be asked about how many reminders they would like to receive about each event and how far in advance they would like to receive the reminder (decided before commencing the study). The carer will record all target events that were forgotten as well as instances of reminding. A text message reminder will also be sent each evening to remind the carer to make the recording.

It will also be important to establish early on whether each participant will be able to enter events themselves onto their smart phone. Following the initial training session familiarising the participant with the process for the intervention, there will be a 3 week block of training sessions on how to use MindMate. This will run concurrently to the intervention phase and will include the provision of a step-by-step guide, alongside illustrated instructions on how to locate, enter, and navigate the app and its Reminder tool. This will include inputting,
editing, or deleting reminder events. The acquisition of this skill does not form part of the aims of this study; however qualitative information will be gathered upon completion of the training.

Following completion of the intervention block, qualitative information will be gathered to evaluate the usefulness of MindMate, to identify its strengths and limitations and to ascertain whether the participant would use the aid in the future. Participants will also be asked to complete a pre and post study questionnaire on eight domains, adapted from the unified theory of acceptance and use of technology (UTAUT) (Venkatesh, Morris, Davis & Davis 2003). These will be administerated at the initial clinical interview and the follow up clinical interview. The UTAUT includes groups of items concerning; performance expectancy (expectancy that the technology will be useful for its purpose); effort expectancy (perception of effort needed to use it); attitude towards the technology; social influence (the influence of others on the use of the technology); facilitating conditions (the extent to which their environment facilitates use of the technology); self-efficacy (estimations of their own ability to use the technology); anxiety (levels of anxiety felt when using the technology) and behavioural intention (an indication of whether the participant is intending to use the technology in the next 6 months). Scores for each item (on a scale of 1 to 6) within each domain can be pooled to give overall scores for each domain at each time point.

**Data Analysis**

Frequencies will be calculated for percentage of target behaviours remembered/missed within a week. It is anticipated that the frequency of events to be remembered will differ on a weekly basis, so percentage of events forgotten will be calculated each week. As well as visual inspection, statistical analysis will also be undertaken.

Visual inspection includes the calculation and transformation of each participant’s performance to a graph for the purpose of visually analysing (a) trend (progress over time), (b) level (magnitude of the data), and (c) stability (variability or “bounce” of the data) (Gast, 2005). The procedure for visual inspection will follow steps as outlined by Land & Gast (2014) using the graphic display and divided into (a) within-condition and (b) between-conditions analysis of data.
Tau-U is a method for measuring data non-overlap between two phases (A and B) (Tau-U; Parker, Vannest, David, & Sauber, 2011). Non-overlap methods do not rely on means, medians, or modes but rather consider individual values of all data points in pairwise comparisons across phases (Parker, Vannest & Davis, 2011). Non-overlapping data as an indicator of performance difference between phases is included in standards for evaluating SCED’s (Horner, Carr, Halle, McGhee, Odom et al., 2005). Tau-U is a “distribution free” nonparametric technique, with an index well-suited for small datasets, and is useful in aggregating data across phases to come up with an overall effect size. Depending on the data, it possesses statistical power of 91-115 percent of parametric tests (Vannest, Parker & Gonen, 2011).

**Power**

In their meta-analysis of SCED studies of prompting technology in acquired brain injury Jamieson et al. (2013) reported medium effect sizes using non-overlap of all pairs methodology. In the present study we anticipate similar levels of effect. It is therefore anticipated that the Tau-U analysis would have sufficient statistical power to detect the anticipated effect size.

**Dissemination**

Once the thesis is completed it will be submitted to the University of Glasgow as part fulfillment of the award of Doctorate in Clinical Psychology. The researcher will explore appropriate academic journals with the academic supervisor and submit for publication. Participants will be given the option of receiving a summary sheet of the findings of the study. This will be discussed with them when the researcher completes the consent form.

**Ethical Issues**

In order to address issues of consent and capacity, psychiatrists responsible for the potential participant’s care will be consulted. All participants will be checked for consent on the day of assessment and throughout the study. As this study is only recruiting participants with Mild Dementia, this should minimise difficulties with capacity to consent in participating. However, if doubt remains, the researcher will discuss with the psychiatrist and if their capacity remains in doubt, the participant will not be recruited or results not included.
Due to the nature of the study, there is a possibility that recording and discussing memory problems may increase the participant/carer’s awareness of them and this may cause distress. Regular contact will be maintained between the researcher and the participant, offering reassurance and advice, in the hope of overcoming any worry.

All information recorded will be on a university encrypted laptop. The data will be backed up on an encrypted memory stick and on the University of Glasgow secure network. Paper copies of completed tests and consent forms will be stored in accordance with local and national Data Protection guidelines, and will be stored in a locked filing cabinet within NHS premises. The researcher and Chief Investigator will have access to the data and upon completion of the study, the Chief Investigator will retain the data. This will be held within the Institute of Mental Health and Wellbeing at the University of Glasgow (Gartnaval Royal Hospital) for ten years. Paper files containing personal information used to contact participants (e.g. name, address) will be destroyed by shredding upon the completion of study. There will be an application to the NHS Research Ethics Committee who will provide feedback on plans to minimise any adverse effects on participants.

**Financial Issues**

Mindmate is a free app, and only participants who already own a smart phone or tablet will be recruited.

The main costs will come from use of response forms for the various neuropsychological tests. These, as well as all miscellaneous costs, are included in the Expenses form (Appendix 1).

**Health and Safety Procedures**

See Appendix 2
Timetable

<table>
<thead>
<tr>
<th>Task</th>
<th>Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission to Ethics</td>
<td>June/July 2016</td>
</tr>
<tr>
<td>Information to OCMHIt’s</td>
<td>September 2016</td>
</tr>
<tr>
<td>Recruitment of Participants</td>
<td>September-November 2016</td>
</tr>
<tr>
<td>Data Collection</td>
<td>January-March 2016</td>
</tr>
<tr>
<td>Analysis and Write-Up</td>
<td>April-May 2016</td>
</tr>
<tr>
<td>Final Write-Up and Preparation for Viva</td>
<td>June-July 2016</td>
</tr>
</tbody>
</table>

References

Alzheimer’s Scotland Action on Dementia (2015)


single-subject research to identify evidence-based practice in special education. 

*Exceptional Children*, 71, 165–179.


